Veterinary Drug terms — page 5 | HESTIA Glossary

Browse all 1,061 veterinary drug terms HESTIA uses to describe agricultural data — with definitions and synonyms. Free and open.

Azithromycin (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-allpha-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one; Azithromycin; Aritromicina [Spanish]
Bacitracin AI3-50147-X
Barbital 5,5-Diethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; barbital; Barbitone; Veronal; 5,5-Diethylbarbituric acid; Ethylbarbital; Diemal; 57-44-3; Diethylmalonylurea; DEBA; Vesperal; Malonal; Uronal; Diethylbarbitone; Dormonal; Hypnogene; Veroletten; Verolettin; Sedeval; Diethylbarbituric acid; Barbitonum; Diemalum; Barbital (VAN); Barbitale [DCIT]; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl-; Barbitalum [INN-Latin]; 5,5-Diethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; Medinal; Diethyl-barbituric acid; Barbituric acid, 5,5-diethyl-; Kyselina 5,5-diethylbarbiturova; 5,5-diethylpyrimidine-2,4,6(1H,3H,5H)-trione; UNII-5WZ53ENE2P; 5,5-diethyl-1,3-diazinane-2,4,6-trione; diethylmalonyl urea; NSC 31352; CCRIS 7420; Kyselina 5,5-diethylbarbiturova [Czech]; CHEBI:31252; EINECS 200-331-2; BRN 0163999; 5WZ53ENE2P; AI3-02727; DEA No. 2145; FTOAOBMCPZCFFF-UHFFFAOYSA-N; NCGC00159419-02; NCGC00159419-04; Barbitale; Barbitalum; DSSTox_CID_2643; DSSTox_RID_76671; DSSTox_GSID_22643; Barbital [INN:JAN]; CAS-57-44-3; Barbital (TN); Barbital [INN:BAN:JAN:NF]; Barbital (JP17/INN); CHEMBL444; Epitope ID:117124; Barbituric acid,5-diethyl-; Oprea1_012884; Oprea1_497227; SCHEMBL43818; 5-24-09-00137 (Beilstein Handbook Reference); DTXSID5022643; CTK8E5105; Barbital 0.1 mg/ml in Methanol; Barbital 1.0 mg/ml in Methanol; Pharmakon1600-01900040; WLN: T6VMVMV FHJ F2 F2; NSC31352; Tox21_111650; NSC-31352; NSC759567; ZINC13545632; AKOS015903028; Tox21_111650_1; Barbital, BioXtra, >=99.0% (T); CCG-214014; DB01483; MCULE-2107172999; NSC-759567; 5,5-Diethyl-pyrimidine-2,4,6-trione; Barbitone|||5,5-Diethylbarbituric acid; NCGC00159419-03; LS-24148; SBI-0207064.P001; TR-020051; FT-0662476; D01740; AB00443731_03; 2,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl-; Q412409; SR-01000872752; SR-01000872752-1; W-105467; BRD-K83359602-001-01-5; Barbital solution, drug standard, 1.0 mg/mL in methanol; Barbital, European Pharmacopoeia (EP) Reference Standard; F0000-0015; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl- (9CI); Barbital solution, 1.0 mg/mL in methanol, certified reference material, ampule of 1 mL; InChI=1/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13; Barbital; 5-24-09-00137 (Beilstein Handbook Reference)
Basic violet 14 4-[(4-Aminophenyl)(4-imino-2,5-cyclohexadien-1-ylidene)methyl]-2-methylbenzenamine hydrochloride (1:1); 4-((4-Aminophenyl)(4-imino-2,5-cyclohexadien-1-ylidene)methyl)-2- methylbenzenamine monohydrochloride; C.I. 42510
Befunolol 1-(7-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]-2-benzofuranyl]ethanone; Befunolol; 2-Acetyl-7-(2-hyroxy-3-isopropylaminopropoxy)benzofuran
Bendroflumethiazide 3,4-Dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Bendroflumethiazide; 4-27-00-08041 (Beilstein Handbook Reference)
Benzimidazole 1H-Benzimidazole; BENZIMIDAZOLE; 51-17-2; 1H-Benzimidazole; 1H-Benzo[d]imidazole; Benzoimidazole; 1,3-Benzodiazole; o-Benzimidazole; 3-Azaindole; Benziminazole; Benzoglyoxaline; Azindole; 1H-Benzoimidazole; 1,3-Diazaindene; Benzimidazol; N,N'-Methenyl-o-phenylenediamine; NSC 759; 1H-1,3-benzodiazole; BZI; UNII-E24GX49LD8; CCRIS 5967; Benzimidazole, 98%; CHEBI:41275; HSDB 2797; EINECS 200-081-4; MFCD00005585; BRN 0109682; AI3-03737; E24GX49LD8; HYZJCKYKOHLVJF-UHFFFAOYSA-N; DSSTox_CID_4573; benzimidazole phase betaetha; benzimidazole phase alphalpha; benzimidazole phase gammaamma; DSSTox_RID_77454; DSSTox_GSID_24573; F3366-5347; CAS-51-17-2; bezimidazole; benz-imidazole; Hbzim; Hbim; 1H-benzimidazol; 4dsu; PubChem11074; ACMC-209ks6; Epitope ID:140095; SCHEMBL6009; SCHEMBL6010; WLN: T56 BM DNJ; 5-23-06-00196 (Beilstein Handbook Reference); KSC270M3P; MLS001066336; BDBM7939; CHEMBL306226; NSC759; SCHEMBL5197771; DTXSID8024573; CTK1H0637; KS-00000KLW; NSC-759; HMS2233D03; HMS3370L16; ZINC331902; Tox21_202107; Tox21_303321; ANW-31204; BBL007563; HTS027706; LS-151; SBB004294; STK397462; AKOS000119163; AM81999; CS-W019944; DB02962; MCULE-8167283494; PS-5765; RTR-018244; NCGC00091255-01; NCGC00091255-02; NCGC00257173-01; NCGC00259656-01; ((non-Isotopelabelled)Benzimidazole-13C6; AK109037; M020; SC-15192; SMR000471839; SY012765; AB1003114; DB-002016; ST2415489; TR-018244; 264-EP2269999A1; 264-EP2270006A1; 264-EP2270010A1; 264-EP2270505A1; 264-EP2271628A1; 264-EP2272517A1; 264-EP2272825A2; 264-EP2272828A1; 264-EP2272832A1; 264-EP2274983A1; 264-EP2275102A1; 264-EP2275105A1; 264-EP2275409A1; 264-EP2275412A1; 264-EP2277858A1; 264-EP2280000A1; 264-EP2280009A1; 264-EP2281563A1; 264-EP2281815A1; 264-EP2281818A1; 264-EP2281819A1; 264-EP2281824A1; 264-EP2284157A1; 264-EP2284920A1; 264-EP2287155A1; 264-EP2289876A1; 264-EP2292586A2; 264-EP2292592A1; 264-EP2292593A2; 264-EP2292611A1; 264-EP2292612A2; 264-EP2294066A1; 264-EP2295433A2; 264-EP2298755A1; 264-EP2298767A1; 264-EP2298770A1; 264-EP2298774A1; 264-EP2301536A1; 264-EP2301538A1; 264-EP2301921A1; 264-EP2301923A1; 264-EP2301925A1; 264-EP2301926A1; 264-EP2301932A1; 264-EP2302003A1; 264-EP2305219A1; 264-EP2305250A1; 264-EP2305640A2; 264-EP2305642A2; 264-EP2305643A1; 264-EP2305651A1; 264-EP2305662A1; 264-EP2305695A2; 264-EP2305696A2; 264-EP2305697A2; 264-EP2305698A2; 264-EP2305769A2; 264-EP2308492A1; 264-EP2308510A1; 264-EP2308562A2; 264-EP2308833A2; 264-EP2308840A1; 264-EP2308852A1; 264-EP2308854A1; 264-EP2308867A2; 264-EP2308870A2; 264-EP2309855A1; 264-EP2311455A1; 264-EP2311810A1; 264-EP2311826A2; 264-EP2311830A1; 264-EP2311831A1; 264-EP2311842A2; 264-EP2314575A1; 264-EP2314582A1; 264-EP2314583A1; 264-EP2314587A1; 264-EP2315303A1; 264-EP2315763A1; 264-EP2316452A1; 264-EP2316459A1; 264-EP2371811A2; 264-EP2371812A1; 264-EP2372804A1; 264-EP2377847A1; 264-EP2378585A1; 658-EP2281819A1; 658-EP2298076A1; 658-EP2298077A1; 658-EP2301353A1; 658-EP2305031A1; 658-EP2305034A1; 658-EP2305035A1; 658-EP2305658A1; B0054; FT-0606545; ST50214470; C02009; 25950-EP2269978A2; 25950-EP2269985A2; 25950-EP2269991A2; 25950-EP2284150A2; 25950-EP2284151A2; 25950-EP2284152A2; 25950-EP2284153A2; 25950-EP2284155A2; 25950-EP2284156A2; 25950-EP2284164A2; 25950-EP2287140A2; 25950-EP2287148A2; 25950-EP2287150A2; 25950-EP2289871A1; 25950-EP2292590A2; 25950-EP2295419A2; 25950-EP2298732A1; 25950-EP2298774A1; 25950-EP2301912A2; 25950-EP2301913A1; 25950-EP2301914A1; 25950-EP2301916A2; 25950-EP2301918A1; 25950-EP2301921A1; 25950-EP2301926A1; 25950-EP2305637A2; 25950-EP2308832A1; 25950-EP2308863A1; 25950-EP2308875A1; 25950-EP2309855A1; 25950-EP2311796A1; 25950-EP2311797A1; 25950-EP2311798A1; 25950-EP2311799A1; 25950-EP2314558A1; 25950-EP2371811A2; 134823-EP2287165A2; 134823-EP2287166A2; 134823-EP2292612A2; 134823-EP2292620A2; Q415190; W-105914; InChI=1/C7H6N2/c1-2-4-7-6(3-1)8-5-9-7/h1-5H,(H,8,9; 157198-80-6; Benzimidazole; 5-23-06-00196 (Beilstein Handbook Reference)
Benzofuran BENZOFURAN; 2,3-Benzofuran; Coumarone; 271-89-6; 1-Benzofuran; Benzo[b]furan; Cumarone; Benzofurfuran; Coumaron; Benzo(b)furan; 1-Oxindene; 1-Oxidene; NCI-C56166; Benzofuran (IUPAC); Cumaron; benzo[b]furane; CCRIS 2384; UNII-LK6946W774; HSDB 4173; NSC 1255; EINECS 205-982-6; benzfuran; BRN 0107704; AI3-17613; CHEMBL363614; CHEBI:35260; IANQTJSKSUMEQM-UHFFFAOYSA-N; MFCD00005847; LK6946W774; NCGC00091088-05; BZF; 2,3-Benzofuran, 99.5%; bezofuran; 1-Oxaindene; 1-Benzofuran #; PubChem7003; DSSTox_CID_141; ACMC-1CR9M; 2,3-Benzofuran, 99%; SCHEMBL5564; DSSTox_RID_75394; DSSTox_GSID_20141; WLN: T56 BOJ; 5-17-02-00003 (Beilstein Handbook Reference); MLS002454357; DTXSID6020141; CTK1A2129; NSC1255; HMS2268K20; LS-25; KS-00000W6C; NSC-1255; ZINC1591814; Tox21_400054; 2,3-Benzofuran, analytical standard; ANW-26149; BDBM50167940; SBB060607; AKOS000121520; AM84862; DB04179; MCULE-3934334695; PS-5764; RTR-012243; NCGC00091088-01; NCGC00091088-02; NCGC00091088-03; NCGC00091088-04; NCGC00091088-06; BR-46635; CAS-271-89-6; SC-03045; SMR000112279; DB-047175; ST2412637; B0060; FT-0609496; FT-0660665; ST51046756; C14512; M-6414; 10195-EP2269978A2; 10195-EP2269985A2; 10195-EP2269991A2; 10195-EP2269992A1; 10195-EP2270010A1; 10195-EP2272832A1; 10195-EP2272972A1; 10195-EP2272973A1; 10195-EP2275401A1; 10195-EP2277858A1; 10195-EP2277872A1; 10195-EP2277874A1; 10195-EP2280000A1; 10195-EP2281563A1; 10195-EP2281818A1; 10195-EP2284150A2; 10195-EP2284151A2; 10195-EP2284152A2; 10195-EP2284153A2; 10195-EP2284155A2; 10195-EP2284156A2; 10195-EP2284157A1; 10195-EP2284164A2; 10195-EP2284174A1; 10195-EP2287140A2; 10195-EP2287148A2; 10195-EP2287150A2; 10195-EP2289871A1; 10195-EP2292586A2; 10195-EP2292590A2; 10195-EP2292592A1; 10195-EP2292593A2; 10195-EP2292604A2; 10195-EP2292611A1; 10195-EP2292630A1; 10195-EP2295419A2; 10195-EP2295429A1; 10195-EP2295432A1; 10195-EP2295433A2; 10195-EP2295503A1; 10195-EP2298732A1; 10195-EP2298766A1; 10195-EP2298767A1; 10195-EP2298770A1; 10195-EP2301536A1; 10195-EP2301538A1; 10195-EP2301912A2; 10195-EP2301913A1; 10195-EP2301914A1; 10195-EP2301916A2; 10195-EP2301923A1; 10195-EP2305219A1; 10195-EP2305637A2; 10195-EP2305648A1; 10195-EP2305651A1; 10195-EP2305695A2; 10195-EP2305696A2; 10195-EP2305697A2; 10195-EP2305698A2; 10195-EP2308510A1; 10195-EP2308562A2; 10195-EP2308832A1; 10195-EP2308840A1; 10195-EP2308849A1; 10195-EP2308850A1; 10195-EP2308854A1; 10195-EP2308863A1; 10195-EP2311455A1; 10195-EP2311796A1; 10195-EP2311797A1; 10195-EP2311798A1; 10195-EP2311799A1; 10195-EP2311825A1; 10195-EP2311842A2; 10195-EP2314558A1; 10195-EP2314575A1; 10195-EP2314587A1; 10195-EP2316452A1; 10195-EP2316459A1; 10195-EP2371811A2; 10195-EP2371812A1; 10195-EP2371831A1; 29075-EP2270505A1; 29075-EP2281815A1; 29075-EP2305640A2; 29075-EP2311842A2; 80096-EP2272517A1; 80096-EP2305250A1; 103410-EP2270101A1; 103410-EP2301924A1; A818947; Q410089; J-640079; J-800081; W-107126; InChI=1/C8H6O/c1-2-4-8-7(3-1)5-6-9-8/h1-6; 5-17-02-00003 (Beilstein Handbook Reference)
Benzothiazole BENZOTHIAZOLE; 95-16-9; BENZO[D]THIAZOLE; 1,3-Benzothiazole; Benzosulfonazole; 1-Thia-3-azaindene; Vangard BT; benzothiazol; USAF EK-4812; benzthiazole; CHEBI:45993; FEMA Number 3256; UNII-G5BW2593EP; O-2857; FEMA No. 3256; CCRIS 7893; HSDB 2796; NSC 8040; EINECS 202-396-2; MFCD00005775; BRN 0109468; AI3-05742; G5BW2593EP; IOJUPLGTWVMSFF-UHFFFAOYSA-N; Benzothiazole, 97%; DSSTox_CID_4586; DSSTox_RID_77458; DSSTox_GSID_24586; CAS-95-16-9; s-benzothiazole; Benzothiazole, 96%; 1,3-Benzothiazole #; ACMC-209rv5; Epitope ID:138946; EC 202-396-2; SCHEMBL8430; WLN: T56 BN DSJ; 4-27-00-01069 (Beilstein Handbook Reference); KSC486M5N; MLS001050134; Benzothiazole, >=96%, FG; CHEMBL510309; SCHEMBL9304593; DTXSID7024586; CTK3I6656; ZINC19726; NSC8040; Benzothiazole, analytical standard; KS-00000FQ0; NSC-8040; Tox21_201853; Tox21_303232; ANW-40383; BDBM50444460; SBB058513; STL268890; AKOS000120178; AC-3297; CS-W013350; FS-4155; LS-1973; MCULE-5257468117; MP-2108; RTR-029662; TRA0008463; NCGC00091399-01; NCGC00091399-02; NCGC00257070-01; NCGC00259402-01; AK105881; BOT; BR-72791; SC-18067; SMR001216577; DB-057562; ST2412661; TR-029662; B0092; FT-0622731; ST51023425; W9729; Benzothiazole, Vetec(TM) reagent grade, 96%; 11895-EP2269978A2; 11895-EP2269985A2; 11895-EP2269991A2; 11895-EP2270010A1; 11895-EP2270113A1; 11895-EP2270505A1; 11895-EP2272828A1; 11895-EP2272832A1; 11895-EP2272935A1; 11895-EP2272972A1; 11895-EP2272973A1; 11895-EP2275105A1; 11895-EP2275409A1; 11895-EP2275411A2; 11895-EP2276085A1; 11895-EP2277858A1; 11895-EP2277869A1; 11895-EP2277872A1; 11895-EP2280000A1; 11895-EP2281563A1; 11895-EP2281818A1; 11895-EP2281824A1; 11895-EP2284150A2; 11895-EP2284151A2; 11895-EP2284152A2; 11895-EP2284153A2; 11895-EP2284155A2; 11895-EP2284156A2; 11895-EP2284157A1; 11895-EP2284164A2; 11895-EP2284920A1; 11895-EP2287140A2; 11895-EP2287148A2; 11895-EP2287150A2; 11895-EP2287165A2; 11895-EP2287166A2; 11895-EP2289871A1; 11895-EP2289876A1; 11895-EP2292586A2; 11895-EP2292590A2; 11895-EP2292592A1; 11895-EP2292593A2; 11895-EP2292611A1; 11895-EP2292620A2; 11895-EP2292630A1; 11895-EP2295419A2; 11895-EP2295421A1; 11895-EP2295433A2; 11895-EP2298732A1; 11895-EP2298767A1; 11895-EP2298828A1; 11895-EP2301534A1; 11895-EP2301912A2; 11895-EP2301913A1; 11895-EP2301914A1; 11895-EP2301916A2; 11895-EP2301923A1; 11895-EP2301983A1; 11895-EP2302003A1; 11895-EP2305219A1; 11895-EP2305637A2; 11895-EP2305642A2; 11895-EP2305643A1; 11895-EP2305651A1; 11895-EP2305652A2; 11895-EP2305662A1; 11895-EP2305675A1; 11895-EP2305695A2; 11895-EP2305696A2; 11895-EP2305697A2; 11895-EP2305698A2; 11895-EP2308510A1; 11895-EP2308562A2; 11895-EP2308832A1; 11895-EP2308840A1; 11895-EP2308849A1; 11895-EP2308850A1; 11895-EP2308854A1; 11895-EP2308863A1; 11895-EP2311451A1; 11895-EP2311796A1; 11895-EP2311797A1; 11895-EP2311798A1; 11895-EP2311799A1; 11895-EP2311842A2; 11895-EP2314575A1; 11895-EP2314582A1; 11895-EP2314587A1; 11895-EP2315303A1; 11895-EP2316450A1; 11895-EP2316459A1; 11895-EP2371810A1; 11895-EP2371811A2; 11895-EP2371812A1; 11895-EP2372804A1; 11895-EP2378585A1; 29076-EP2272517A1; 29076-EP2277868A1; 29076-EP2277869A1; 29076-EP2277870A1; 29076-EP2281815A1; 29076-EP2305250A1; 29076-EP2305640A2; 29076-EP2305671A1; 29076-EP2305675A1; 29076-EP2305769A2; 29076-EP2311826A2; 29076-EP2311842A2; 62566-EP2308812A2; 87422-EP2270018A1; 87422-EP2298780A1; 87422-EP2305689A1; AC-907/25014160; Q419096; Q-100900; F0001-2268; Z1245735190; InChI=1/C7H5NS/c1-2-4-7-6(3-1)8-5-9-7/h1-5; O-2857
Benzoylecgonine (1R,2R,3S,5S)-3-(Benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid; Benzoylecgonine; Benzoylecgonine
Benzyl isothiocyanate (Isothiocyanatomethyl)benzene; benzyl isothiocyanate; 622-78-6; Benzylisothiocyanate; (Isothiocyanatomethyl)benzene; Benzyl mustard oil; Benzylsenfoel; Tromacaps; Tromalyt; Urogran; Benzyl-isothiocyanate; Isothiocyanic acid, benzyl ester; Benzene, (isothiocyanatomethyl)-; isothiocyanatomethylbenzene; Isothiocyanic Acid Benzyl Ester; Benzylsenfoel [German]; AB 2 (VAN); alpha-isothiocyanatotoluene; Isothiocyanotaomethylbenzene; isothiocyanatomethyl-benzene; UNII-871J6YOR8Q; NSC 118976; Toluene, alpha-isothiocyanato-; BITC; CCRIS 3145; EINECS 210-753-9; MFCD00004819; Benzyl isothiocyanate, 98%; BRN 0386135; (isothiocyanatomethyl)-benzene; CHEMBL55285; AI3-02736; 871J6YOR8Q; AB 2; CHEBI:17484; Toluene, .alpha.-isothiocyanato-; MDKCFLQDBWCQCV-UHFFFAOYSA-N; NSC118976; Benzylsenfoel (german); phenylmethanisothiocyanate; PMITC cpd; SR-05000002381; phenylmethyl isothiocyanate; Tromocaps; Benzyl isothio cyanate; PubChem14549; Spectrum_001820; SpecPlus_000684; Tromalyt active substance; DSSTox_CID_155; Spectrum2_000852; Spectrum3_000793; Spectrum4_001059; Spectrum5_001837; WLN: SCN1R; ACMC-209n1k; NCIMech_000859; alpha-Isothiocyanato-Toluene; isothiocyanato-methyl-benzene; DSSTox_RID_75407; DSSTox_GSID_20155; SCHEMBL44145; BSPBio_002526; KBioGR_001358; KBioSS_002323; 4-12-00-02276 (Beilstein Handbook Reference); KSC250O3D; Benzene, isothiocyanatomethyl-; DivK1c_006780; SPECTRUM1503006; SPBio_000863; (Isothiocyanatomethyl)benzene #; 1-(isothiocyanatomethyl)benzene; BITC, 17; Toluene, alpha -isothiocyanato-; DTXSID0020155; CTK1F0731; FEMA 4428; KBio1_001724; KBio2_002321; KBio2_004889; KBio2_007457; KBio3_001746; KS-00001PQO; TIMTEC-BB SBB002731; AKOS JY2090023; Benzyl isothiocyanate, 98%, FG; OTAVA-BB 1055640; HMS1921P18; Pharmakon1600-01503006; (Isothiocyanatomethyl)benzene, 9CI; KS-00000V2U; ZINC1529592; AKOS BBS-00004442; Tox21_201191; ANW-34134; BBL013129; BDBM50240520; CCG-35868; NSC758206; s4783; SBB002731; STK399787; AKOS000212138; AS04379; LS-7216; LS11773; MCULE-5989558191; NSC-118976; NSC-758206; RTR-033289; SDCCGMLS-0066697.P001; QTL1_000013; NCGC00094982-01; NCGC00094982-02; NCGC00094982-03; NCGC00094982-04; NCGC00258743-01; Benzyl isothiocyanate, analytical standard; BP-12924; CAS-622-78-6; HY-77813; NCI60_000455; PS-10308; SC-13625; SBI-0052749.P002; DB-022613; TR-033289; CS-0006958; FT-0622167; I0224; ST50214559; C03098; AB00053249_03; J-650076; SR-05000002381-1; SR-05000002381-2; Q18341725; F0001-1663; 58019-05-9; Benzyl isothiocyanate; 4-12-00-02276 (Beilstein Handbook Reference)
Benzylamine BENZYLAMINE; Benzenemethanamine; phenylmethanamine; 100-46-9; Monobenzylamine; (Phenylmethyl)amine; alpha-Aminotoluene; 1-phenylmethanamine; (Aminomethyl)benzene; N-Benzylamine; Moringine; Phenylmethylamine; Sumine 2005; Aminotoluene; benzyl amine; Sumine 2006; omega-Aminotoluene; .omega.-Aminotoluene; benzyl-amine; a-Aminotoluene; 1utj; 1utn; 2bza; NSC 8046; UNII-A1O31ROR09; .alpha.-Aminotoluene; CHEBI:40538; HSDB 2795; EINECS 202-854-1; MFCD00008106; 89551-24-6; TOLUENE,ALPHA-AMINO; CHEMBL522; BRN 0741984; AI3-15299; A1O31ROR09; WGQKYBSKWIADBV-UHFFFAOYSA-N; Benzylamine, 99%, pure; ABN; Benzylamine, 99.5+%, AcroSeal(R); benzylarnine; bezylamine; aminomethylbenzene; N-(phenylmethyl)amine; BnNH2; NH2Bn; QuadraPure(TM) BZA; Bzl-NH2; Benzenemethanamine, 9CI; Aminomethylated polystyrene; Benzylamine, reagent grade; DSSTox_CID_1839; SCHEMBL373; ACMC-20aj53; Epitope ID:141489; EC 202-854-1; QuadraPure(TM) Benzylamine; DSSTox_RID_76359; NCIOpen2_007746; DSSTox_GSID_21839; 4-12-00-02155 (Beilstein Handbook Reference); KSC178S3P; laquo Omegaraquo -aminotoluene; Benzylamine, analytical standard; DTXSID5021839; BDBM10999; CTK0H8937; NSC8046; NSC-8046; STR00195; ZINC6096244; Benzylamine, ReagentPlus(R), 99%; Tox21_300933; MFCD00130502; MFCD08561140; SBB040473; STL115534; AKOS000119096; QuadraPure BZA, 400-1100 micron; DB02464; EBD2211112; MCULE-6894874255; RTR-000182; TRA0015888; KS-000002M7; NCGC00166029-01; NCGC00166029-02; NCGC00254835-01; CAS-100-46-9; LS-43150; SC-22771; ST2413668; TR-000182; B0406; FT-0622834; FT-0622836; ST45255426; AZ0001-0093; Benzylamine, for GC derivatization, >=99.0%; C15562; 13743-EP2269992A1; 13743-EP2270010A1; 13743-EP2272517A1; 13743-EP2277848A1; 13743-EP2277881A1; 13743-EP2280001A1; 13743-EP2280008A2; 13743-EP2281563A1; 13743-EP2281818A1; 13743-EP2284171A1; 13743-EP2284172A1; 13743-EP2284174A1; 13743-EP2287141A1; 13743-EP2287163A1; 13743-EP2289891A2; 13743-EP2289892A1; 13743-EP2292593A2; 13743-EP2295406A1; 13743-EP2295414A1; 13743-EP2295420A1; 13743-EP2295429A1; 13743-EP2295432A1; 13743-EP2295437A1; 13743-EP2298729A1; 13743-EP2298775A1; 13743-EP2298779A1; 13743-EP2305250A1; 13743-EP2305651A1; 13743-EP2305654A1; 13743-EP2305666A1; 13743-EP2305678A1; 13743-EP2305687A1; 13743-EP2305695A2; 13743-EP2305696A2; 13743-EP2305697A2; 13743-EP2305698A2; 13743-EP2308510A1; 13743-EP2308562A2; 13743-EP2308812A2; 13743-EP2308838A1; 13743-EP2308841A2; 13743-EP2308851A1; 13743-EP2308854A1; 13743-EP2308867A2; 13743-EP2308870A2; 13743-EP2311804A2; 13743-EP2311815A1; 13743-EP2311837A1; 13743-EP2314593A1; 13743-EP2316836A1; 13743-EP2371810A1; 13743-EP2371811A2; 13743-EP2380871A1; 13925-EP2295437A1; 13925-EP2298775A1; 13925-EP2298776A1; 13925-EP2308833A2; 13925-EP2311837A1; 13925-EP2314586A1; 13925-EP2316836A1; Benzylamine, purified by redistillation, >=99.5%; Q424000; BRD-K76133116-001-01-2; Z54748260; F2190-0388; 3F830B2A-ABAA-4E26-971C-53B1C7485954; InChI=1/C7H9N/c8-6-7-4-2-1-3-5-7/h1-5H,6,8H; QuadraPure(R) BZA, 400-1100 mum, extent of labeling: 20 mg/g loading, macroporous; 4-12-00-02155 (Beilstein Handbook Reference)
Bergapten 4-Methoxy-7h-furo[3,2-g][1]benzopyran-7-one; Bergapten; 5-Methoxypsoralen; 484-20-8; bergaptene; Heraclin; Majudin; 4-Methoxy-7H-furo[3,2-g]chromen-7-one; BERGAPTAN; Psoraderm; 5-Mop; 5-Methoxy psoralen; O-Methylbergaptol; 5-Methoxy-6,7-furanocoumarin; 5-Methoxyfuranocoumarin; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-methoxy-; Pentaderm; 4-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 4-methoxyfuro[3,2-g]chromen-7-one; 4-Methoxyfuro[3,2-g]benzopyran-7-one; 5-methoxypsoralene; UNII-4FVK84C92X; NSC 95437; Bergaptene (DCF); 4-methoxy-7H-furo[3,2-g][1]benzopyran-7-one; CCRIS 4348; HSDB 3466; 5-Methoxypsoralen with ultraviolet A therapy; NSC95437; 6-Hydroxy-4-methoxy-5-benzofuranacrylic acid, gamma-lactone; EINECS 207-604-5; 4-Methoxy-furo[3,2-g]chromen-7-one; 7H-Furo(3,2-g)(1)benzopyran-7-one, 4-methoxy-; BRN 0019560; CHEMBL24171; 4FVK84C92X; BGEBZHIAGXMEMV-UHFFFAOYSA-N; NSC-95437; 5-methoxyfurano[3,2-g]chromen-2-one; 4-Methoxyfuro[3,2-g]benzopyrane-7-one; AK134854; 5-Methoxypsoralen, 98%; DSSTox_CID_5560; DSSTox_RID_77830; DSSTox_GSID_25560; Q-100536; 5 methoxypsoralen; CAS-484-20-8; SMR000112435; SR-05000002173; Geralen; Bergapten(e); Pentaderm (TN); 5-methoxy-psoralen; Spectrum_000794; 5-methoxy-2H-furo[3,2-g]chromen-2-one; Spectrum2_000534; Spectrum3_000663; Spectrum4_001478; Spectrum5_000155; 5-Methoxypsoralen, 99%; 5-Methoxypsoralen; Heraclin; bmse000758; 5-Methoxypsoralen (obsol.); 7H-Furo[3, 4-methoxy-; Oprea1_562364; SCHEMBL50066; BSPBio_002325; KBioGR_002055; KBioSS_001274; SPECTRUM300546; 5-19-06-00004 (Beilstein Handbook Reference); MLS002207272; MLS002454380; Bergapten, analytical standard; DivK1c_000529; 5-Methoxypsoralen (Bergapten); SPBio_000547; MEGxp0_000990; DTXSID1025560; ACon0_000984; ACon1_001979; CHEBI:18293; CTK3J2399; HMS501K11; KBio1_000529; KBio2_001274; KBio2_003842; KBio2_006410; KBio3_001545; KS-00000GSD; ZINC57731; NINDS_000529; HMS1923G13; HMS2268M24; HMS3652F19; Pharmakon1600-00300546; BCP30865; HY-N0370; TNP00299; Tox21_202357; Tox21_303255; ANW-42611; BDBM50067880; CCG-39946; MFCD00010272; NSC755877; s4239; STK333038; AKOS000276715; CB-1199; CS-2234; DB12216; DS-2970; LS-1292; MCULE-7768334865; NSC-755877; RTR-017690; SDCCGMLS-0066492.P001; IDI1_000529; NCGC00017357-01; NCGC00017357-02; NCGC00017357-03; NCGC00017357-04; NCGC00017357-05; NCGC00017357-06; NCGC00017357-07; NCGC00017357-08; NCGC00091582-01; NCGC00091582-02; NCGC00091582-03; NCGC00091582-04; NCGC00178705-01; NCGC00178705-02; NCGC00256998-01; NCGC00259906-01; 4CN-0945; AC-20189; CC-24574; NCI60_042121; SC-46077; ST057259; SBI-0051583.P002; 4-methoxy-7-furo[3,2-g][1]benzopyranone; AB0019675; AX8014410; DB-051552; ST2411501; TR-017690; 4-Methoxy-7H-furo[3,2-g]benzopyran-7-one; B2840; FT-0603416; N1304; SW220008-1; V0122; 4-Methoxy-7H-furo[3,2-g]chromen-7-one #; C01557; D07521; M-9412; AB00052148_06; AB00052148_07; 484B208; A827532; C-11626; Q414779; SR-05000002173-2; SR-05000002173-3; SR-05000002173-5; BRD-K12968785-001-02-6; BRD-K12968785-001-03-4; BRD-K12968785-001-06-7; BRD-K12968785-001-11-7; 6-Hydroxy-4-methoxy-5-benzofuranacrylic acid, .gamma.-lactone; InChI=1/C12H8O4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6H,1H; 5-Methoxypsoralen; 5-19-06-00004 (Beilstein Handbook Reference)
Betadex beta-Cyclodextrin; beta-CYCLODEXTRIN; Betadex; Cyclomaltoheptaose; Cycloheptaglucan; Cycloheptaamylose; Cycloheptaglucosan; 7585-39-9; beta-Cycloamylose; beta-CD; Kleptose; Cycloheptapentylose; beta-cyclodextrine; UNII-JV039JZZ3A; Kleptose B; Rhodocap N; Ringdex B; Ringdex BL; .beta.-Cyclodextrin; JV039JZZ3A; Caraway; Schardinger beta-dextrin; b-Cyclodextrin; beta-Dextrin; CHEBI:495055; Dextrin, beta-cyclo; beta-Cycloheptaamylose; NCGC00090771-01; DSSTox_CID_358; CYCLO-HEPTA-AMYLOSE; DSSTox_RID_75536; DSSTox_GSID_20358; CCRIS 651; EINECS 231-493-2; NSC 314334; beta-Cyclodextrins; CAS-7585-39-9; AI3-29233; Cyclodextrin B; Beta cyclodextrin; Betadex [USAN:INN:BAN:NF]; 1dmb; 2zyn; beta-cyclo-dextrin; E459; Betadex (NF/INN); Schardinger A-Dextrin; 2y4s; 3ck8; 3m3r; BDBM11; EC 231-493-2; beta-Cyclodextrin, >=97%; SCHEMBL24215; CHEMBL415690; INS NO.459; DTXSID1020358; INS-459; WHGYBXFWUBPSRW-FOUAGVGXSA-N; heptakis(hydroxymethyl)[?]tetradecol; Tox21_111017; Tox21_201006; EBD952338; AKOS015900444; Tox21_111017_1; DB03995; NCGC00090771-02; NCGC00090771-03; NCGC00090771-04; NCGC00258559-01; HY-107201; CS-0027620; E-459; ST24050411; C-9120; C13183; D02401; C-23612; Q27077120; Betadex, European Pharmacopoeia (EP) Reference Standard; D047392000; beta-Cyclodextrin, produced by Wacker Chemie AG, Burghausen, Germany; Beta Cyclodextrin, United States Pharmacopeia (USP) Reference Standard; beta-Cyclodextrin, powder, BioReagent, suitable for cell culture, >=97%; Beta-Cyclodextrin, Pharmaceutical Secondary Standard; Certified Reference Material; beta-Cyclodextrin, produced by Wacker Chemie AG, Burghausen, Germany, >=95.0% (HPLC); (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.2~3,6~.2~8,11~.2~13,16~.2~18,21~.2~23,26~.2~28,31~]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol (non-preferred name); beta-Cyclodextrin, Produced by Wacker Chemie AG, Burghausen, Germany, Life Science, >=98.0% (HPLC); beta-Cyclodextrin hydrate; 68168-23-0; beta-CYCLODEXTRIN; beta-Cyclodextrin hydrate, 99%; MFCD00150811; SCHEMBL692932; JNSAKCOAFBFODP-ZQOBQRRWSA-N; AKOS025310932; P997; beta-Cyclodextrin hydrate, puriss., >=99.0% (HPLC); 218269-29-5; Betadex; AI3-29233
Betamethasone (11beta,16beta)-9-Fluro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; Betamethasone; 4-08-00-03501 (Beilstein Handbook Reference)
Betulinic acid (3beta)-3-Hydroxylup-20(29)-en-28-oic acid; Betulinic acid; Betulinic acid
Bezafibrate 2-[4-[2-[(4-Chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid; Bezafibrate; Bezafibrat
Bicine N,N-Bis(2-hydroxyethyl)glycine; Bicine; 150-25-4; N,N-Bis(2-hydroxyethyl)glycine; Diethylolglycine; Dihydroxyethylglycine; Diethanol glycine; Bicene; 2-(bis(2-hydroxyethyl)amino)acetic acid; N,N-Di(2-hydroxyethyl)glycine; N,N-Dihydroxyethylglycine; N,N-Dihydroxyethyl glycine; Fe-3-Specific; Glycine, N,N-bis(2-hydroxyethyl)-; DHEG; Bis(2-Hydroxyethyl)glycine; N,N-(2-Hydroxyethyl)glycine; 2-[bis(2-hydroxyethyl)amino]acetic acid; MFCD00004295; N,N-Bis(2-hydroxyethyl)aminoacetic acid; N,N-Bis(beta-hydroxyethyl)glycine; NSC 7342; GLYCINE, N,N-DIHYDROXYETHYL-; UNII-1J484QFI1O; N,N-Bis(hydroxyethyl)glycine; N,N-(2-Dihydroxyethyl)glycine; EINECS 205-755-1; BRN 1769362; 1J484QFI1O; FSVCELGFZIQNCK-UHFFFAOYSA-N; bicine buffer; N,N-Bis(.beta.-hydroxyethyl)glycine; AK-43217; Glycine,N-dihydroxyethyl-; WLN: QV1N2Q2Q; W-201338; Bicine, 99+%, for analysis; Glycine,N-bis(2-hydroxyethyl)-; Bicine, 99+%, for biochemistry; di(hydroxyethyl)glycine; Diethanolglycine; N,N-di(hydroxyethyl)glycine; SCHEMBL34161; 4-04-00-02390 (Beilstein Handbook Reference); KSC495E2D; nn-bis(2-hydroxyethyl)glycine; di(hydroxyethyl)aminoacetic acid; DTXSID3041669; CHEBI:40957; CTK3J5221; KS-00000FRI; n n-bis(2-hydroxyethyl) glycine; n,n-bis(2-hydroxyethyl) glycine; n,n-bis-(2-hydroxyethyl)glycine; BIB1151; BICINE, >=99% (titration); N,N-bis(2-hydroxyethyl)glycine]; NSC7342; NSC7512; N,N-bis(2-hydroxyethyl)-Glycine; ZX-AFC000791; HMS3604E14; ADAL1018228; BB_SC-02565; NSC-7342; NSC-7512; ZINC1683490; ANW-21269; BBL011024; GB1591; s6276; SBB057746; STK802165; AKOS005622671; BICINE HIGH PURITY GRADE 100G; DB03709; MCULE-4763691774; RTR-006124; n n-di(hydroxyethyl)-b-aminoacetic acid; n,n-di(hydroxyethyl)-b-aminoacetic acid; [Bis(2-hydroxyethyl)amino]acetic acid #; BICINE, BioUltra, >=99.5% (T); BICINE, BioXtra, >=99% (titration); NCGC00342441-01; AS-12494; CC-31733; LS-72526; N,N-Bis-(2-hydroxyethyl)aminoacetic acid; SC-15868; SY010805; N,N-bis-(2-hydroxyethyl) aminoacetic acid; [bis-(2-hydroxy-ethyl)-amino]-acetic acid; AB0012025; AX8116657; TR-006124; B0484; FT-0622946; ST24027612; ST50308630; A-8630; AB00443773-03; C-35199; Q4903636; BICINE 30% PEG 600 solution, 0.1 M, pH 9.0+/-0.2 ( in neat); Bicine, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production., suitable for cell culture; Bicine; 4-04-00-02390 (Beilstein Handbook Reference)
Bicuculline [R-(R*,S*)]-6-(5,6,7,8-Tetrahydro-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)furo[3,4-e]-1,3-benzodioxol-8(6H)-one; (+)-Bicuculline; bicuculline; d-Bicuculline; 485-49-4; Bicculine; Bicucullin; Bicuculline (+); UNII-Y37615DVKC; NSC 32192; C20H17NO6; EINECS 207-619-7; BRN 0098786; CHEBI:3092; CHEMBL417990; Y37615DVKC; (6R)-6-[(5S)-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]furo[3,4-e][1,3]benzodioxol-8(6H)-one; NSC32192; Furo(3,4-e)-1,3-benzodioxol-8(6H)-one, 6-(5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (R-(R*,S*))-; (6R)-6-((5S)-6-methyl(5,6,7,8-tetrahydro-2H-1,3-dioxolano[4,5-g]isoquinolin-5- yl))-6-hydro-2H-1,3-dioxoleno[4,5-e]isobenzofuran-8-one; (R)-6-((S)-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuro[5,4-d][1,3]dioxol-8(6H)-one; Furo[3,4-e]-1,3-benzodioxol-8(6H)-one, 6-[(5S)-5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl]-, (6R)-; SR-01000075252; (6R)-6-[(5S)-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6H-furo[3,4-g][1,3]benzodioxol-8-one; Bicuculline,(+); Prestwick_96; Furo(3,4-e)-1,3-benzodioxol-8(6H)-one, 6-((5S)-5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (6R)-; Prestwick0_000589; Prestwick1_000589; Prestwick2_000589; Prestwick3_000589; Biomol-NT_000252; (+)-Bicuculline, 98%; SCHEMBL8222; Lopac0_000234; BSPBio_000438; 4-27-00-06900 (Beilstein Handbook Reference); MLS002153892; DivK1c_000609; SPBio_002657; BPBio1_000482; BPBio1_000794; GTPL2312; DTXSID3042687; HMS501O11; KBio1_000609; AOB5192; NINDS_000609; HMS1569F20; HMS2096F20; HMS2235H18; HMS3266A07; HMS3414D19; HMS3652N20; HMS3678D19; BCP04180; HY-N0219; BDBM50000693; MFCD00005006; NSC-32192; PDSP2_000138; s7071; ZINC19899011; AKOS024282673; API0002224; CCG-204329; CS-5493; DB11562; IDI1_000609; NCGC00017385-06; (+)-Bicuculline, >=97.0% (TLC); 6-(5,6,7,8-Tetrahydro-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)furo(3,4-e)1,3-benzodioxol-8(6H)one; AS-17471; LS-70680; SC-17991; SMR001233241; ST057559; ST057706; AB0019776; FT-0080946; N1592; SW196408-2; V0271; A12590; B 9130; C09364; 485B494; C-21058; Q3639734; SR-01000075252-1; SR-01000075252-4; SR-01000075252-5; WLN: T C566 DO FO KN EH&&TJ K1 J- ET B565 CVO JO LO EH KHJ; (6R)-6-[(5S)-6-Methyl-5,6,7,8-tetrahydro-2H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-2H-furo[3,4-e][1,3]benzodioxol-8(6H)-one; (6R)-6-[(5S)-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6H-furo[3,4-e][1,3]benzodioxol-8-one; (6R)-6-[(5S)-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6H-furo[4,3-g][1,3]benzodioxol-8-one; (bicuculline) 6-Methyl-5-(8-oxo-6,8-dihydro-furo[3'',4'':3,4]benzo[1,2-d][1,3]dioxol-6-yl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-6-ium; (R)-6-((S)-6-Methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6H-furo[3'',4'':3,4]benzo[1,2-d][1,3]dioxol-8-one; [R-(R*,S*)]-6-(5,6,7,8-Tetrahydro-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)furo[3,4-e]-1,3-benzodioxol-8(6H)-one; 6-((5S)-6-methyl-5,6,7,8-tetrahydro-2H-1,3-dioxoleno[4,5-g]isoquinolin-5-yl)-6 -hydro-2H-1,3-dioxoleno[4,5-e]isobenzofuran-8-one; 6-(6-Methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6H-furo[3'',4'':3,4]benzo[1,2-d][1,3]dioxol-8-one; 6-(6-Methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6H-furo[3'',4'':3,4]benzo[1,2-d][1,3]dioxol-8-one (Bicuculline); 6-(6-Methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6H-furo[3'',4'':3,4]benzo[1,2-d][1,3]dioxol-8-one(bicuculline); Furo[3,3-benzodioxol-8(6H)-one, 6-(5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)-, [R-(R*,S*)]-; H0Z; Bicuculline; 4-27-00-06900 (Beilstein Handbook Reference)
Bicyclomycin Bicozamycin
Biotin (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanoic acid; Biotin; AI3-51198
Bisphenol A 4,4'-(1-Methylethylidene)bisphenol; Bisphenol A; 80-05-7; 2,2-Bis(4-hydroxyphenyl)propane; 4,4'-Isopropylidenediphenol; Bisphenol; Diphenylolpropane; 4,4'-Bisphenol A; Diano; 4,4'-(propane-2,2-diyl)diphenol; Biphenol A; DIAN; Parabis A; Rikabanol; p,p'-Bisphenol A; p,p'-Isopropylidenebisphenol; Bisphenol-A; 2,2-Bis(p-hydroxyphenyl)propane; 2,2-Di(4-phenylol)propane; Bisferol A; Phenol, 4,4'-(1-methylethylidene)bis-; Ipognox 88; p,p'-Dihydroxydiphenylpropane; Pluracol 245; 4,4'-Dihydroxydiphenylpropane; 4-[2-(4-hydroxyphenyl)propan-2-yl]phenol; Dimethylmethylene-p,p'-diphenol; BPA; p,p'-Isopropylidenediphenol; Bis(4-hydroxyphenyl)propane; Ucar bisphenol A; 2,2-Di(4-hydroxyphenyl)propane; Ucar bisphenol HP; 4,4'-Isopropylidene diphenol; 2,2-Bis(hydroxyphenyl)propane; p,p'-Dihydroxydiphenyldimethylmethane; 4,4'-(1-Methylethylidene)bisphenol; 4,4'-propane-2,2-diyldiphenol; 4,4'-Isopropylidenebisphenol; Bis(4-hydroxyphenyl)dimethylmethane; Isopropylidenebis(4-hydroxybenzene); Bis(4-hydroxyphenyl) dimethylmethane; Bisphenol A.; 4,4'-Dihydroxy-2,2-diphenylpropane; 4,4'-Dihydroxydiphenyldimethylmethane; 2,2-Bis-4'-hydroxyfenylpropan; 2,2-(4,4'-Dihydroxydiphenyl)propane; Phenol, 4,4'-isopropylidenedi-; Phenol, (1-methylethylidene)bis-; Dimethylbis(p-hydroxyphenyl)methane; NCI-C50635; 2,2-Bis(4'-hydroxyphenyl)propane; 4,4' Isopropylidinediphenol; Bisferol A [Czech]; Dimethyl bis(p-hydroxyphenyl)methane; 2,2-Bis (4-hydroxyphenol) propane; beta-di-p-hydroxyphenylpropane; 4,4'-Dihydroxydiphenyl-2,2-propane; 4-[1-(4-hydroxyphenyl)-1-methylethyl]phenol; Bis(p-hydroxyphenyl)propane; Phenol, 4,4'-dimethylmethylenedi-; CCRIS 95; 4,4[-Isopropylidenediphenol; Propane, 2,2-bis(p-hydroxyphenyl)-; beta,beta'-Bis(p-hydroxyphenyl)propane; UNII-MLT3645I99; 4,4'-Dimethylmethylenediphenol; HSDB 513; 4,4'-Isopropylidenebis[phenol]; Bisphenol A (BPA); 2,2-bis[4-Hydroxyphenyl]propane; 4,4-ISOPROPYLIDENEDIPHENOL; 2,2-bis(4-hydroxyphenyl) propane; NSC 1767; EINECS 201-245-8; beta,beta-di-(p-hydroxyphenyl)propane; BRN 1107700; 2,2-Bis-4'-hydroxyfenylpropan [Czech]; 4,4'-Dihydroxdiphenylpropane; Noname; 4,4'-(1-Methylethane-1,1-diyl)diphenol; AI3-04009; DTXSID7020182; CHEBI:33216; bisphenol A, disodium salt; IISBACLAFKSPIT-UHFFFAOYSA-N; di-2,2-(4-Hydroxyphenyl)propane; MLT3645I99; 2, 2-Bis(4-hydroxyphenyl)propane; 4,4'-ISOPROPYLIDENEDIPHENOL (BISPHENOL A); Polycarbonate; 4,2-propane; 2,2-(4,4-Dihydroxydiphenyl)propane; 2,2-di-(4'-Hydroxyphenyl)-propane; 4,2-diphenylpropane; MFCD00002366; 2,2-Bis(4,4'-hydroxyphenyl)propane; bis(4-hyd roxyphenyl) dimethylmethane; NCGC00090952-07; .beta.,.beta.'-Bis(p-hydroxyphenyl)propane; DSSTox_CID_182; DSSTox_RID_75420; Phenol,4'-isopropylidenedi-; DSSTox_GSID_20182; Phenol,4'-dimethylmethylenedi-; 2,4'-Dihydroxydiphenyl)propane; WLN: QR DX1&1&R DQ; Propane,2-bis(p-hydroxyphenyl)-; .beta.-Di-(p-hydroxyphenyl)propane; 4,4'-Isopropylidenediphenol, 97%; Phenol,4'-(1-methylethylidene)bis-; CAS-80-05-7; 4-[1-(4-hydroxyphenyl)-isopropyl]phenol; bisphenol A, sodium salt; bis-phenol-a; bis-phenol A; Bis Phenol A; Millad HBPA; 2OH; 4,4'-ISOPROPYLIDENE-DIPHENOL; Phenol, 4,4'-(1-methylethylidene)bis-, homopolymer; 4,4'-bisphenol-A; Bisphenol A, 97%; PubChem22174; 2e2r; 2p7g; 4, 4'-Bisphenol A; Bisphenol A, >=99%; EC 201-245-8; 4,4'-(1-Methylethylidene)bisphenol homopolymer; Bisphenol a(ring 13c12); Poly(Bisphenol A carbonate); BIDD:PXR0120; Oprea1_215541; p, p'-Isopropylidenediphenol; SCHEMBL15062; bis(4-hydroxyphenyl)-propane; 27100-33-0; 4-06-00-06717 (Beilstein Handbook Reference); KSC448A9R; MLS001055461; BIDD:ER0208; 4,4'-Isopropylidenedi-Phenol; p, p'-Dihydroxydiphenylpropane; (1-methylethylidene)bis-Phenol; 2, 2-Di(4-phenylol)propane; 4,4'-Isopropylidenediphenol B; ACMC-20977c; CHEMBL418971; GTPL7865; 4, 4'-Dihydroxydiphenylpropane; 2, 2-Bis(hydroxyphenyl)propane; .beta.-di-p-hydroxyphenylpropane; 4,4'-Dimethylmethylenedi-Phenol; BDBM29608; beta-Di-(p-hydroxyphenyl)propane; CTK3E8098; ZINC56434; BPA 157; NSC1767; 2,2-bis(p-hydroxyphenyl)-propane; Bisphenol A - Polycarbonate Grade; HMS2866B07; HMS3749E11; KUC105370N; 2,2'-Bis(4-hydroxyphenyl)propane; 2,2-di(p-hydroxy-phenyl-)propane; 4,4'-Isopropylidenediphenol, 8CI; 2,2-bis-(p-hydroxyphenyl)-propane; CS-B1737; NSC-1767; NSC17959; 2,2-bis-(4-hydroxy phenyl)propane; 2,2-bis-(4-hydroxyphenyl) propane; 2,2-bis-(4-hydroxyphenyl)-propane; Tox21_202992; Tox21_400088; ANW-13606; BBL010647; dimethyl bis(p-hydroxyphenyl)methane; KSC-7-199; NSC-17959; s6007; SBB012432; STK801675; 2,2-bis-(4- hydroxyphenyl)-propane; p, p'-Dihydroxydiphenyldimethylmethane; 4,4'-(1-methylethylidene)bis-phenol; 4,4'-dihydroxy diphenyl-2,2-propane; AKOS000119022; 4, 4'-Dihydroxydiphenyl-2,2-propane; 4, 4'-Dihydroxydiphenyldimethylmethane; CCG-214370; DB06973; LS-1788; MCULE-1016303245; NE10183; RTR-025374; beta, beta'-Bis(p-hydroxyphenyl)propane; Bisphenol A 100 microg/mL in Methanol; UPCMLD0ENAT5883875:001; NCGC00090952-01; NCGC00090952-02; NCGC00090952-03; NCGC00090952-04; NCGC00090952-05; NCGC00090952-06; NCGC00090952-08; NCGC00090952-09; NCGC00260537-01; O169; SC-62333; SMR000315090; ST065685; VS-02603; 4,4'-(1-Methylethylidene)bisphenol, 9CI; TR-025374; 1,1'-(1-Methylethylidene)bisphenylol, 9CI; B0494; FT-0609178; ST24042488; 4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenol; C13624; 4,4'-Isopropylidenediphenol, analytical standard; A839823; AE-848/01247026; Q271980; SR-01000596928; SR-01000596928-1; BRD-K41494493-001-04-7; Bisphenol A, certified reference material, TraceCERT(R); F1284-0895; Z256709694; Bisphenol A, United States Pharmacopeia (USP) Reference Standard; InChI=1/C15H16O2/c1-15(2,11-3-7-13(16)8-4-11)12-5-9-14(17)10-6-12/h3-10,16-17H,1-2H; Bisphenol A; 4-06-00-06717 (Beilstein Handbook Reference)
Bleomycin a2 Bleomycin; bleomycin; Bleocin; Bleomicin; Bleomycins; Bleomycine [INN-French]; Bleomycinum [INN-Latin]; Bleomicina [INN-Spanish]; bleomycin a2; 11056-06-7; CCRIS 2754; Bleomycin sulfate; HSDB 3208; NDC 0015-3010; BleomiciNSC 125066; Bleomycine; Bleomycinum; Bleomycin A(2); Bleomycin B(2); Bleomycin [INN]; Bleomycin [INN:BAN]; BLM; SCHEMBL21090952; C55H85N17O21S3; LMPK14000006; LS-524; DB00290; bleomycin; Isobleomycin A2; bleomycin a2; 11056-06-7; Bleomycin sulfate; Bleomycinamide, 3(sup B)-O-de(aminocarbonyl)-N(sup 1)-(3-(dimethylsulfonio)propyl)-, 2(sup B)-carbamate; NCIMech_000876; CHEMBL439180; CTK8I9468; NSC146842; NSC-146842; LS-44899; 9041-93-4; Q26998364; bleomycin a2; bleomycin; 11116-31-7; CHEBI:3139; Zhengguangmycin A2 [Chinese]; EINECS 234-356-5; Bleomycinamide, N1-[3-(dimethylsulfonio)propyl]-; N1-(3-(Dimethylsulfonio)propyl)bleomycinamide; Bleo; Bleomycinamide, N1-(3-(dimethylsulfonio)propyl)-; Bleomycin hydrochloride; 11056-06-7; NSC-125066; SCHEMBL134155; CHEMBL403664; DTXSID20872327; BLM; C55H86N17O21S3; AKOS032960358; LS-44860; C06854; N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide; Q26841044; UNII-40S1VHN69B component OYVAGSVQBOHSSS-UAPAGMARSA-O; bleomycin; Zhengguangmycin A2; bleomycin a2; Bleogin; 11056-06-7; Bleomycin A2 & Bleomycin B2.; Pingyangmyvin A2; NSC125066; SCHEMBL2385791; bleomycin; 11056-06-7; LS-190691; Bleocin
Brefeldin A (1R,2E,6S,10E,11aS,13S,14aR)-1,6,7,8,9,11a,12,13,14,14a-Decahydro-1,13-dihydroxy-6-methyl-4H-cyclopent[f]oxacyclotridecin-4-one; Brefeldin A; Ascotoxin
Brilliant green N-[4-[[4-(Diethylamino)phenyl]phenylmethylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium, Sulfate (1:1); C.I. Basic Green 1; C.I. 42040
Bromazepam 7-Bromo-1,3-dihydro-5-(2-pyridinyl)-2H-1,4-benzodiazepin-2-one; bromazepam; Compedium; Durazanil; Lexotanil; Creosedin; Lectopam; Lexaurin; Lexilium; Lekotam; Lexomil; Lexotan; Calmepam; Compendium; Normoc; 1812-30-2; Ultramidol; LA Xvii; Bromazepamum [INN-Latin]; Bromazepamum [Latin]; Ro 5-3350; Pasca; oi,; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiazepin-2(1H)-one; KL 001; KL-001; Bromazepam [USAN:INN:BAN:JAN]; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; NSC 140669; UNII-X015L14V0O; 2H-1,4-Benzodiazepin-2-one, 7-bromo-1,3-dihydro-5-(2-pyridinyl)-; EINECS 217-322-4; 7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzdiazepin-2-one; 1,3-Dihydro-7-bromo-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; BRN 0618645; DEA No. 2748; VMIYHDSEFNYJSL-UHFFFAOYSA-N; 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-bromo-5-(2-pyridyl)-; X015L14V0O; 2H-1,4-BENZODIAZEPIN-2-ONE, 7-BROMO-1,3-DIHYDRO-5-(2-PYRIDYL)-; NSC-140669; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiaxepin-2(1H)-one; Bromazepamum; Lectopam (TN); Ro 53350; Ro 4-9253; 7-Bromo-5-[2-pyridyl]-3H-1,4-benzodiaxepin-2[1H]-one; Bromazepam civ; Lexomil|||Lexotanil; SCHEMBL43933; 5-26-05-00078 (Beilstein Handbook Reference); MLS003899212; Bromazepam, analytical standard; CHEMBL277062; ZINC1051; Bromazepam (JP17/USAN/INN); CHEBI:31302; CTK7H4369; DTXSID40171081; 7-Bromo-1,4-benzodiazepin-2-one; Bromazepam 0.1 mg/ml in Methanol; Bromazepam 1.0 mg/ml in Methanol; 7-bromo-1,3-dihydro-5-(2-pyridinyl)-2h-1,4-benzodiazepin-2-one; NSC140669; Ro-53350; DB01558; LS-34139; SMR000058724; RO-5-3350; WLN: T67 GMV JN IHJ CE K- BT6NJ; FT-0663608; D01245; 2H-1, 7-bromo-1,3-dihydro-5-(2-pyridyl)-; 2H-1, 7-bromo-1,3-dihydro-5-(2-pyridinyl)-; 812B302; Bromazepam, drug standard, 1.0 mg/mL in methanol; C-46042; Q422435; Bromazepam, European Pharmacopoeia (EP) Reference Standard; Bromazepam, United States Pharmacopeia (USP) Reference Standard; 7-bromo-5-(pyridin-2-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one; 7-bromo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one; (E)-7-bromo-5-(pyridin-2-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one; 7-Bromo-5-(2-pyridinyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one #; Bromazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Bromazepam; 5-26-05-00078 (Beilstein Handbook Reference)
Bromochloro-5,5-dimethylimidazolidine-2,4-dione 32718-18-6; Bromochloro-5,5-dimethylimidazolidine-2,4-dione; EINECS 251-171-5; 5-(bromomethyl)-5-(chloromethyl)imidazolidine-2,4-dione; CTK8D4567; AKOS015913695; VZ21264; FT-0623227; EINECS 251-171-5
Bromocriptine (5'alpha)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; bromocriptine; Bromocryptine; Bromocriptin; Bromoergocryptine; 25614-03-3; Bromoergocriptine; Bromergocryptine; 2-Bromo-alpha-ergocryptine; Parlodel; 2-Bromo-alpha-ergokryptine; BromocriptiBromocriptinum; 2-Bromo-alpha-ergokryptin; Bromocriptinum [INN-Latin]; Bromocriptina [INN-Spanish]; CB-154; Bromocriptine methanesulfonate; UNII-3A64E3G5ZO; C32H40BrN5O5; CCRIS 3244; 2-Bromoergocryptine; EINECS 247-128-5; 3A64E3G5ZO; CHEBI:3181; Ergoset; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; Bromocryptin; Ergocryptine, 2-bromo-; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; 2-Bromoergokryptine; Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'alpha)-; Bromocriptine [BAN]; NSC169774; Bromocriptine [USAN:BAN:INN]; 2-Bromoergocryptine Methanesulfonate; Bromocriptine (USAN/INN); SR-01000075356; Bromocriptine [USAN:INN:BAN]; NCGC00024584-03; 08Y; Bromocriptine+ (GTP-); Prestwick0_000121; Prestwick1_000121; Prestwick2_000121; Carboprost Methylate,(S); DSSTox_CID_2687; Biomol-NT_000005; CHEMBL493; GTPL35; DSSTox_RID_76692; DSSTox_GSID_22687; Lopac0_000171; SCHEMBL25297; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; BIDD:GT0464; SPBio_002101; BPBio1_001131; DTXSID1022687; SANDOZ 15-754; BDBM81993; Ergocryptine, 2-bromo- (8CI); OZVBMTJYIDMWIL-AYFBDAFISA-N; Tox21_110907; PDSP2_001500; ZINC53683151; AKOS015961273; CCG-204266; DB01200; SDCCGSBI-0050159.P003; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo; NCGC00024584-04; NCGC00024584-05; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; AC-13601; Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)-; LS-64540; NCI60_001365; 10b-hydroxy-5-isobutyl-2-isopropyl-3,6-; CAS-25614-03-3; C06856; D03165; hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 13177-EP2272832A1; 13177-EP2275420A1; 13177-EP2277876A1; 13177-EP2280008A2; 13177-EP2287165A2; 13177-EP2287166A2; 13177-EP2292614A1; 13177-EP2292620A2; 13177-EP2295412A1; 13177-EP2295413A1; 13177-EP2295439A1; 13177-EP2298731A1; 13177-EP2298738A1; 13177-EP2298779A1; 13177-EP2311808A1; 13177-EP2311818A1; 13177-EP2311829A1; 13177-EP2311837A1; 13177-EP2316470A2; 13177-EP2316834A1; 88085-EP2298415A1; 88085-EP2298742A1; 88085-EP2305648A1; Q413581; J-016067; SR-01000075356-5; (6aR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-; [2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-; BRD-K14496212-001-01-1; BRD-K14496212-066-04-8; (4R,7R)-10-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman; (5alpha,5'beta)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman; Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-,(5'-alpha)-; N-[(2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxo-8,9,10,10a-tetrahydro-5H-oxazolo[[?]]pyrrolo[[?]]pyrazin-2-yl]-bromo-methyl-[?]carboxamide; Bromocriptine; Bromergocryptine
Bromoform Tribromomethane; Bromoform; tribromomethane; 75-25-2; Methane, tribromo-; Tribrommethan; Methenyl tribromide; Methyl tribromide; Tribrommethaan; Tribromometan; Bromoforme; Bromoformio; CHBr3; RCRA waste number U225; NCI-C55130; Bromoforme [French]; Bromoformio [Italian]; Tribrommethaan [Dutch]; Tribrommethan [German]; Tribromometan [Italian]; UNII-TUT9J99IMU; NSC 8019; CCRIS 98; HSDB 2517; DIKBFYAXUHHXCS-UHFFFAOYSA-N; EINECS 200-854-6; UN2515; TUT9J99IMU; RCRA waste no. U225; BRN 1731048; AI3-28587; CHEBI:38682; MFCD00000128; Bromoform, 96%, stabilized; Bromoform, 99+%, stabilized; Bromoform [USP]; MBR; bromo form; tribromo methane; Bromoform; Tri bromo methane; WLN: EYEE; Bromoform, technical grade; DSSTox_CID_1374; DSSTox_RID_76118; DSSTox_GSID_21374; SCHEMBL18691; 4-01-00-00082 (Beilstein Handbook Reference); BIDD:ER0622; Bromoform, puriss., 97.0%; CHEMBL345248; DTXSID1021374; CTK2H7247; KS-00000UEQ; Bromoform [UN2515] [Poison]; NSC8019; Tribromomethane; methyl tribromide; LS-64; Bromoform [UN2515] [Poison]; BCP10566; NSC-8019; ZINC8101061; Tox21_200189; ANW-41206; SBB070879; Bromoform 100 microg/mL in Methanol; AKOS009031540; Bromoform 5000 microg/mL in Methanol; DB03054; EBD2204869; InChI=1/CHBr3/c2-1(3)4/h1; RTR-024224; TRA0036266; UN 2515; CAS-75-25-2; Bromoform, puriss., >=99.0% (GC); NCGC00091318-01; NCGC00091318-02; NCGC00257743-01; BP-21414; I606; SC-81767; Tribromomethane 100 microg/mL in Methanol; TR-024224; B0806; FT-0623248; S0653; C14707; Bromoform, amylene stabilized, analytical standard; Q409799; J-519947; Bromoform, contains 1-3% ethanol as stabilizer, 96%; F0001-1896; Bromoform - contains 60-120ppm 2-Methyl-2-butene as stabilizer; Bromoform, contains 60-120 ppm 2-methyl-2-butene as stabilizer, 99%; Bromoform; 4-01-00-00082 (Beilstein Handbook Reference)
Broxuridine 5-Bromo-2'-deoxyuridine; 5-BROMO-2'-DEOXYURIDINE; 59-14-3; Broxuridine; Bromodeoxyuridine; 5-Bromodeoxyuridine; 5-BrdU; BRDU; BUDR; 5-Bromouracil deoxyriboside; Bromouracil deoxyriboside; 5-Bromodesoxyuridine; 5-Bdu; Broxuridinum; 5-Bromo-2-deoxyuridine; Broxuridina; 5-Bromouracil-2-deoxyriboside; C9H11BrN2O5; NSC-38297; Uridine, 5-bromo-2'-deoxy-; Broxuridinum [INN-Latin]; Broxuridina [INN-Spanish]; Bromoouridine; Radibud; CCRIS 818; Brudr; UNII-G34N38R2N1; HSDB 7477; CHEBI:472552; EINECS 200-415-9; MFCD00006529; 5-Budr; 5-bromo-2'-deoxy uridine; BRN 0030395; CHEMBL222280; 5-Bromo-1-(2-deoxy-beta-D-ribofuranosyl)uracil; G34N38R2N1; 5-Bromo-2'-deoxyuridine (BRDU); NCGC00090770-05; NSC 38297; 5-bromo-2'-desoxyuridine; DSSTox_CID_13105; DSSTox_RID_79051; DSSTox_GSID_33105; 5-Bromo-2'-deoxyuridine, 99+%; BDU; CAS-59-14-3; 1-[(4S,2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-bromo-1,3-dihydropyrim idine-2,4-dione; 5-bromo-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; SMR001227189; Broxuridine [INN]; Broxuridine [INN:JAN]; (+)-5-Bromo-2'-deoxyuridine; 5-bromo-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione; AK-44014; 5-Bromo-dURD; 5-brom-2'-desoxyuridin; Broxuridine (JAN/INN); Maybridge4_003385; Epitope ID:138105; cid_6035; Lopac0_000212; SCHEMBL27755; 4-24-00-01234 (Beilstein Handbook Reference); KSC911S7T; MLS001055406; MLS002153366; DTXSID7033105; CTK8B1979; 5-Bromo-2'-deoxyuridine(BRDU); 5-Bromo-2'-deoxyuridine, 97%; WOVKYSAHUYNSMH-RRKCRQDMSA-N; ZX-AFC000364; HMS1619B05; HMS3039G15; HMS3260L05; BCP21681; KS-00000JJ3; ZINC1081243; 5-BROMO-2''-DEOXY URIDINE; Tox21_111016; Tox21_200106; Tox21_500212; ANW-33171; BDBM50207303; BI2048; BrdU (5-Bromo-2?? -deoxyuridine); CB-072; HG1160; LS-250; SBB002964; STL530083; AKOS001715166; AKOS016015753; AKOS037495737; Tox21_111016_1; CCG-204307; CS-3028; DB12028; LP00212; MCULE-5086148258; SDCCGSBI-0050200.P002; uridine, 3-15N-5-bromo-2'-deoxy-; 5-Bromo-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; NCGC00090770-01; NCGC00090770-02; NCGC00090770-03; NCGC00090770-04; NCGC00090770-06; NCGC00090770-07; NCGC00090770-08; NCGC00090770-09; NCGC00175901-01; NCGC00257660-01; NCGC00260897-01; AS-11762; BR-44014; CC-21273; HY-15910; SC-18439; ST057095; AB0010697; AX8021654; 5-Bromo-2'-deoxyuridine, >=99% (HPLC); EU-0100212; 5-Bromo-2'-deoxyuridine, BioUltra, >=99%; 5-Bromo-2'-deoxyuridine, >=99.0% (HPLC); B 5002; D01763; S-2807; 5- Br-2 inverted exclamation mark -deoxyuridine; 006B529; 140455-EP2277565A2; 140455-EP2277566A2; 140455-EP2277567A1; 140455-EP2277568A2; 140455-EP2277569A2; 140455-EP2277570A2; 140455-EP2292280A1; 156905-EP2284178A2; 156905-EP2284179A2; C-30689; Q419861; SR-01000075718; J-700086; SR-01000075718-1; Br-dU; 5-Bromo-1-(2-deoxy-beta-D-ribofuranosyl)uracil; Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone; (+)-5-bromo-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]- pyrimidine-2,4-dione; 5-bromo-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-4-hydroxypyrimidin-2(1H)-one; 396726-49-1; 5-bromo-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyridine-2,4(1H,3H)-dione; 5-bromo-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 5-bromo-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione; Bromodeoxyuridine; 4-24-00-01234 (Beilstein Handbook Reference)
Budesonide budesonide; Rhinocort; Entocort; 51333-22-3; Preferid; Budeson; Rhinocort Aqua; Pulmicort; Cortivent; Micronyl; Respules; Spirocort; Bidien; Entocort EC; Pulmicort Respules; Budesonidum; Uceris; Rhinocort alpha; Pulmicort Flexhaler; Budesonidum [INN-Latin]; Budesonido [INN-Spanish]; Budesonide [USAN:INN:BAN:JAN]; S 1320; CCRIS 5230; CHEBI:3207; MAP-0010; EINECS 257-139-7; MLS000028507; Budesonide MMX; VOVIALXJUBGFJZ-KWVAZRHASA-N; 51372-29-3; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; S-1320; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; Budenofalk; Budesonido; Horacort; SMR000058337; C25H34O6; Budecort Inhaler; (+)-16alpha,17alpha-Butylidenedioxy-11beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16A(R),17-(BUTYLIDENEBIS(OXY))-11B,21-DIHYDROXYPREGNA-1,4-DIENE-3,20-DIONE; Pregna-1,4-diene-3,20-dione,16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11beta,16alpha)-; (R)-Budesonide; Inflammide; Budiair; Miflonide; Pulmaxan; Fvolir; Rhinocort Allergy; Pulmaxan turbohaler; Pulmicort (TN); Pulmicort Topinasal; Rhinocort (TN); Pregna-1,4-diene-3,20-dione, 16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11-beta,16-alpha)-; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; Pulmicort turbuhaler; Budesonide Easyhaler; Entocort EC (TN); SR-01000000101; Jorveza; Eltair; Ultesa; Budesonide (JAN/USAN/INN); Noex; Giona Easyhaler; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; CPD000058337; Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-, (11.beta.,16.alpha.)-; Prestwick_840; MFCD00083259; Uceris (TN); Budesonide, >=99%; Opera_ID_1696; Prestwick0_000518; Prestwick1_000518; Prestwick2_000518; Prestwick3_000518; Epitope ID:161750; B 7777; SCHEMBL4096; CHEMBL1370; Lopac0_000174; BSPBio_000475; MLS001077323; MLS002207112; SPBio_002396; BPBio1_000523; GTPL7434; DTXSID8020202; HSDB 8279; BBC/768; MAP0010; R01AD05; HMS1569H17; HMS2096H17; HMS2232D17; HMS3259H07; HMS3260D09; HMS3413B08; HMS3413P17; HMS3677B08; HMS3677P17; HMS3713H17; ACT03247; BCP05589; Tox21_500174; BDBM50354850; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; AKOS015969655; AB03148; AC-4697; ACN-043365; API0024660; CCG-204269; CS-2063; DB01222; KS-1162; LP00174; LS-7235; NC00626; SDCCGSBI-0050162.P002; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; NCGC00021318-05; NCGC00021318-06; NCGC00089747-04; NCGC00260859-01; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; HY-13580; SC-71383; B3909; EU-0100174; ST24046248; 5301-EP2270008A1; 5301-EP2280006A1; 5301-EP2281563A1; 5301-EP2281813A1; 5301-EP2281815A1; 5301-EP2281819A1; 5301-EP2292617A1; 5301-EP2292619A1; 5301-EP2295402A2; 5301-EP2295408A1; 5301-EP2301933A1; 5301-EP2305640A2; 5301-EP2305659A1; 5301-EP2308562A2; 5301-EP2311818A1; 5301-EP2311827A1; 5301-EP2314590A1; 5301-EP2316459A1; 5301-EP2371811A2; D00246; 333B223; Q422212; J-504150; Q-101375; SR-01000000101-2; SR-01000000101-6; BRD-A34299591-001-03-4; 16a(R),17-(Butylidenebis(oxy))-11b,21-dihydroxypre; Budesonide, European Pharmacopoeia (EP) Reference Standard; Budesonide, United States Pharmacopeia (USP) Reference Standard; Budesonide, Pharmaceutical Secondary Standard; Certified Reference Material; (11?,16?)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16?,17-[(1RS)-Butylidenebis(oxy)]-11?,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione; (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-Hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-6b-Glycoloyl-5-hydroxy-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one; (6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one
Bufotenine Bufotenin; Bufotenine; Bufotenin; N,N-Dimethylserotonin; Mappin; N,N-Dimethyl-5-hydroxytryptamine; Cinobufotenine; Cohoba; Mappine; Dimethylserotonin; 487-93-4; DM5-HT; 5-Hydroxy-N,N-dimethyltryptamine; 3-(2-Dimethylaminoethyl)-5-indolol; 3-[2-(Dimethylamino)ethyl]-1H-indol-5-ol; Mapine; 3-[2-(Dimethylamino)ethyl]-5-indolol; 3-[2-(Dimethylamino)ethyl]indol-5-ol; NSC 89593; UNII-0A31347TZK; 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-[beta-(Dimethylamino)ethyl]-5-hydroxyindole; EINECS 207-667-9; 1H-Indol-5-ol, 3-[2-(dimethylamino)ethyl]-; 3-(2-Dimethylaminoethyl)indol-5-ol; BRN 0160628; CHEBI:3210; CHEMBL416526; Indol-5-ol, 3-[2-(dimethylamino)ethyl]-; DEA No. 7433; 3-(2-(Dimethylamino)ethyl)-1H-indol-5-ol; 1H-Indol-5-ol, 3-(2-(dimethylamino)ethyl)-; 0A31347TZK; NCGC00247724-01; 3-(.beta.-Dimethylaminoethyl)-5-hydroxyindole; INDOL-5-OL, 3-(2-(DIMETHYLAMINO)ETHYL)-; N,N-Dimethyl-5-HT; 5-OH-DMT; N, N-Dimethylserotonin; 3-(2-dimethylaminoethyl)-1H-indol-5-ol; 2963-79-3; DMT,5-OH; DSSTox_CID_28820; DSSTox_RID_83089; DSSTox_GSID_48894; Oprea1_475603; GTPL144; 5-22-12-00026 (Beilstein Handbook Reference); SCHEMBL518028; ZINC1070; DTXSID0048894; CTK6I0591; VTTONGPRPXSUTJ-UHFFFAOYSA-N; 5-Hydroxy-N, N-dimethyltryptamine; NSC89593; Tox21_112890; BDBM50024206; NSC-89593; PDSP1_000007; PDSP2_000007; STK368137; AKOS005445162; Bufotenine 1.0 mg/ml in Acetonitrile; WLN: T56 BMJ D2N1&1 GQ; DB01445; VZ36427; 3-[(2-Dimethylamino)ethyl]-5-indolol; 3-[2-(Dimethylamino)ethyl]-Indol-5-ol; CAS-487-93-4; LS-83677; {3-[(2-Dimethylamino)ethyl]-5-indolol}; DB-012579; TC-061237; FT-0623282; 1H-Indol-5-ol,3-[2-(dimethylamino)ethyl]-; 3-[2-(Dimethylamino)ethyl]-1H-indol-5-ol #; C08299; Indol-5-ol, {3-[2-(dimethylamino)ethyl]-}; {3-[(beta-Dimethylamino)ethyl]-5-hydroxyindole}; 1H-Indol-5-ol, {3-[2-(dimethylamino)ethyl]-}; 3-[(.beta.-Dimethylamino)ethyl]-5-hydroxyindole; 3-[.beta.-(Dimethylamino)ethyl]-5-hydroxyindole; L001128; Q408915; 3-(2-(Dimethylamino)ethyl)-1H-indol-5-ol (ACD/Name 4.0); 1,5-benzoxazepin-4(5H)-one, 2,3-dihydro-8-methoxy-2,2,5,6-tetramethyl-; 8-methoxy-2,2,5,6-tetramethyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one; Bufotenine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material; InChI=1/C12H16N2O/c1-14(2)6-5-9-8-13-12-4-3-10(15)7-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H; 5-22-12-00026 (Beilstein Handbook Reference)
Busulphan 1,4-Butanediol, 1,4-Dimethanesulfonate; Busulfan; C.B. 2041
Buthionine sulphoximine 2-Amino-4-(S-butylsulfonimidoyl)butanoic acid; Buthionine sulfoximine
Butyramide Butanamide; Butyramide; Butanamide; 541-35-5; n-Butyramide; N-BUTYLAMIDE; Butanimidic acid; Butanoic acid, amide; UNII-9J6OR937VR; butyroamide; n-C3H7C(O)NH2; 9J6OR937VR; CHEBI:50724; DNSISZSEWVHGLH-UHFFFAOYSA-N; butyrylamide; MFCD00041894; Butyramid; n-butanamide; HSDB 5684; NSC 8424; Amide C4; EINECS 208-776-4; n-propyl carboxamide; AI3-24199; ACMC-1B0Z5; C3H7C(O)NH2; CHEMBL1231396; DTXSID8060248; CTK1H1037; DNSISZSEWVHGLH-UHFFFAOYSA-; Butyramide, >=98.0% (T); NSC8424; NSC-8424; ZINC1586734; ANW-31971; LMFA08010018; AKOS008937485; DB02121; MCULE-2712067671; NE10980; SC-46377; TC-120716; B0809; FT-0623345; EN300-61108; 101963-EP2275469A1; 101963-EP2287940A1; 101963-EP2289965A1; 101963-EP2301983A1; A829983; Q5003189; Z33546461; InChI=1/C4H9NO/c1-2-3-4(5)6/h2-3H2,1H3,(H2,5,6); n-Butylamide; AI3-24199
Butyric acid Butanoic acid; Butyric acid; 4-02-00-00779 (Beilstein Handbook Reference)
C.I. Basic Violet 1 Basic Violet 1; C.I. 42535
Cadaverine 1,5-Pentanediamine; Pentane-1,5-diamine; 1,5-Diaminopentane; cadaverine; 462-94-2; 1,5-pentanediamine; pentamethylenediamine; Cadaverin; 1,5-Pentamethylenediamine; Animal coniine; UNII-L90BEN6OLL; AI3-26937; BRN 1697256; EINECS 207-329-0; L90BEN6OLL; CHEMBL119296; CHEBI:18127; VHRGRCVQAFMJIZ-UHFFFAOYSA-N; MFCD00008239; 1,5-Diaminopentane, 98%; N2P; Pentamethylenediamine dihydrochloride; HSDB 7866; Cadaverine, 95%; Pentane-1,5-damne; 1,5-diamino-pentane; BioDex 1-; 1,5-Amylene diamine; ACMC-1BNDU; 1,5-Diamino-n-pentane; alpha,omega-Pentanediamine; bmse000072; EC 207-329-0; SCHEMBL21367; 4-04-00-01310 (Beilstein Handbook Reference); KSC236G7F; Cadaverine, analytical standard; H2N(CH2)5NH2; SCHEMBL5495920; DTXSID5075448; CTK1D6372; KS-00000X5R; ZINC1529253; ANW-30426; BBL027704; BDBM50323741; SBB079706; STL372961; AKOS005169829; AM61576; Cadaverine, purum, >=97.0% (GC); DB03854; MCULE-3785554987; RTR-032211; TRA0169589; NCGC00166285-01; AS-30673; AB0062729; DB-051367; LS-101555; ST2413656; TR-032211; FT-0082782; FT-0600435; ST51045499; Z4773; C01672; M-5203; 462D942; Q161555; J-523897; InChI=1/C5H14N2/c6-4-2-1-3-5-7/h1-7H; 1948270A-6D1B-4F40-BC13-9B680ED17B17; Cadaverine; 4-04-00-01310 (Beilstein Handbook Reference)
Calcifediol (epsilonR,1R,3aS,4E,7aR)-4-[(2Z)-2-[(5S)-5-Hydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-alpha,alpha,epsilon,7a-tetramethyl-1H-indene-1-pentanol; Calcifediol; Calcifediol
Canertinib N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; Canertinib
Cannabidiol 2-[[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol; Cannabidiol; 1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-
Captopril 1-[(2S)-3-Mercapto-2-methyl-1-oxopropyl]-L-proline; captopril; 62571-86-2; Capoten; L-Captopril; Lopirin; Captopryl; Cesplon; Captolane; Tensoprel; Acepress; Captoril; Dilabar; Garranil; Hypertil; Tenosbon; Alopresin; Acepril; Lopril; Captoprilum; Acediur; Aceplus; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; Isopresol; Tensobon; Apopril; Asisten; Captoprilum [INN-Latin]; SQ 14225; SQ-14225; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; Lopirin [Switzerland]; SQ 14,225; SA 333; D-3-Mercapto-2-methylpropionylproline; 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; (2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; UNII-9G64RSX1XD; 3-Mercapto-2-methylpropionyl-proline; Hipertil; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; CHEBI:3380; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; HSDB 6527; L-Proline, 1-[(2S)-3-mercapto-2-methyl-1-oxopropyl]-; L-Proline, 1-(3-mercapto-2-methyl-1-oxopropyl)-, (S)-; EINECS 263-607-1; 9G64RSX1XD; CHEMBL1560; 1-[(2S)-3-Mercapto-2-methyl-1-oxopropyl]-L-proline; C9H15NO3S; MLS000069484; 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); FAKRSMQSSFJEIM-RQJHMYQMSA-N; (-)-Captopril; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline; Captopril, 98%; MFCD00168073; NCGC00023654-04; SMR000059061; 1-Pyrrolidinecarboxylic acid, 1-(D-3-mercapto-2-methyl-1-propionyl)-, L-(S,S)-; DSSTox_CID_17197; DSSTox_RID_79306; DSSTox_GSID_37197; SQ-14534; L-Proline, 1-((2S)-3-mercapto-2-methyl-1-oxopropyl)-; Novocaptopril; Captril; Farcopril; Hypopress; Tensiomin; Zapto; Captopril (Capoten); (S)-1-((S)-3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxylic acid; Capozide (Salt/Mix); X8Z; Apopril (TN); Capoten (TN); Captopril [USAN:INN:BAN:JAN]; 1-[(2s)-3-mercapto-2-methylpropionyl]-l-proline; SR-01000075603; component of Captea (Salt/Mix); component of Acezide (Salt/Mix); component of Ecazide (Salt/Mix); SQ-14,225; SQ-14,534; (2S)-1-((2S)-2-methyl-3-sulfanylpropanoyl)pyrrolidine-2-carboxylic acid; Captopril,(S); Prestwick_103; Captopril [USAN:USP:INN:BAN:JAN]; SQ14534; SCHEMBL4; Spectrum_000688; Opera_ID_1041; Prestwick3_000019; Spectrum2_001211; Spectrum3_001388; Spectrum4_000811; Spectrum5_001587; Lopac-C-4042; 1-((2S)-2-Methyl-3-sulfanylpropanoyl)-L-proline #; Epitope ID:114065; UPCMLD-DP003; C 4042; Lopac0_000302; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline; BSPBio_000057; BSPBio_002976; KBioGR_001321; KBioSS_001168; MLS001076488; DivK1c_000208; SPECTRUM1500682; SPBio_001022; Captopril (JP17/USP/INN); (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; BPBio1_000063; GTPL5158; DTXSID1037197; UPCMLD-DP003:001; BDBM21642; HMS500K10; KBio1_000208; KBio2_001168; KBio2_003736; KBio2_006304; KBio3_002196; KS-00000XHT; ZINC57001; C09AA01; 1j37; NINDS_000208; HMS1921C12; HMS2089P19; HMS2092I12; HMS2095C19; HMS2233I04; HMS3259G10; HMS3260N06; HMS3712C19; Pharmakon1600-01500682; HY-B0368; Tox21_110890; Tox21_500302; BBL033600; CCG-39104; EI-213; KM0635; NSC757419; s2051; SA-333; SBB017523; STK802012; AKOS005622581; Captopril, >=98% (HPLC), powder; Tox21_110890_1; AB04252; BCP9000485; CS-2425; DB01197; KS-5025; LP00302; MCULE-1716939647; NC00554; NSC-757419; SDCCGSBI-0050290.P006; IDI1_000208; SMP1_000056; NCGC00015235-01; NCGC00015235-02; NCGC00023654-03; NCGC00023654-05; NCGC00023654-06; NCGC00023654-07; NCGC00023654-08; NCGC00023654-09; NCGC00023654-10; NCGC00023654-11; NCGC00023654-13; NCGC00260987-01; AC-12047; CPD000059061; SAM002564201; ST079562; SBI-0050290.P004; AB0007072; AB2000455; Captopril, meets USP testing specifications; LS-137465; SQ -14225; EU-0100302; FT-0082749; ((S)-3-mercapto-2-methylpropanoyl)-L-proline; BIM-0050290.0001; C06867; D00251; J10167; 54254-EP2269989A1; 54254-EP2270011A1; 54254-EP2272841A1; 54254-EP2277879A1; 54254-EP2287165A2; 54254-EP2287166A2; 54254-EP2292620A2; 54254-EP2295406A1; 54254-EP2298742A1; 54254-EP2298772A1; 54254-EP2298776A1; 54254-EP2298779A1; 54254-EP2301923A1; 54254-EP2301931A1; 54254-EP2301936A1; 54254-EP2305219A1; 54254-EP2305648A1; 54254-EP2308562A2; 54254-EP2308839A1; AB00052156-16; AB00052156_17; AB00052156_18; 571C862; Q421119; SR-01000000039; 1-[(2S)-3-Mercapto-2-methylpropionyl]- L-proline; SR-01000000039-2; SR-01000075603-1; SR-01000075603-3; 1-[(S)-3-mercapto-2-methyl-1-oxopropyl]-L-proline; BRD-K54529596-001-04-0; BRD-K54529596-001-15-6; Captopril, British Pharmacopoeia (BP) Reference Standard; Z2786051697; Captopril, European Pharmacopoeia (EP) Reference Standard; Captopril, United States Pharmacopeia (USP) Reference Standard; Captopril, Pharmaceutical Secondary Standard; Certified Reference Material; L-?Proline, 1-?[(2S)?-?3-?mercapto-?2-?methyl-?1-?oxopropyl]?-; Captopril for system suitability, European Pharmacopoeia (EP) Reference Standard; Captopril; Acediur
Carbachol 2-[(Aminocarbonyl)oxy]-N,N,N-trimethylethanaminium chloride; Carbachol; P. V. Carbachol
Carbamazepine 5H-Dibenz[b,f]azepine-5-carboxamide; carbamazepine; 298-46-4; Tegretol; Carbamazepen; 5H-Dibenzo[b,f]azepine-5-carboxamide; Carbazepine; Finlepsin; Biston; Equetro; Carbamezepine; Tegretal; Epitol; 5H-Dibenz[b,f]azepine-5-carboxamide; Carbatrol; Neurotol; Timonil; Karbamazepin; Stazepine; Telesmin; Lexin; Tegretol-Xr; Carbamazepin; benzo[b][1]benzazepine-11-carboxamide; Carbamazepina; Carbamazepinum; Amizepin; Bipotrol; Teril; Geigy 32883; 5-Carbamyl-5H-dibenzo(b,f)azepine; 5-Carbamoyl-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine-5-carboxamide; Calepsin; Carnexiv; 5-Carbamoyl-5H-dibenz(b,f)azepine; 5-Carbamoyl-5H-dibenz[b,f]azepine; G 32883; G-32883; NSC 169864; Carbamazepinum [INN-Latin]; Carbamazepina [INN-Spanish]; CHEBI:3387; UNII-33CM23913M; HSDB 3019; FFGPTBGBLSHEPO-UHFFFAOYSA-N; EINECS 206-062-7; CHEMBL108; BRN 1246090; 5-Carbamyldibenzo(b,f)azepine; MLS000069652; 5-Carbamoyldibenzo(b,f)azepine; CBZ; dibenzo[b,f]azepine-5-carboxamide; MFCD00005073; NSC169864; 33CM23913M; Carbamazepine, 98%; NSC-169864; Tegretol,Carbamazepine; NCGC00015234-11; AK116064; CAS-298-46-4; SMR000058201; Stazepin; DSSTox_CID_2731; 2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene-2-carboxamide; DSSTox_RID_76704; DSSTox_GSID_22731; Q-200792; Carbazepin; 5H-dibenzo[b,f]azepine-5-carboxamide; Oxcarbazepine IMpurity A; Amizepine; Carbelan; Sirtal; Tegretol Cr; SMR001227191; SR-01000000229; Carbatrol extended-release; Trimonil; Neurotop retard; Tegretol (TN); Prestwick_104; Equetro (TN); Carbamazepine [USAN:INN:BAN:JAN]; Carbamazepine, powder; Opera_ID_72; Spectrum_000096; Carbamazepine [USAN:USP:INN:BAN:JAN]; carbamazepine (Tegretol); Prestwick0_000052; Prestwick1_000052; Prestwick2_000052; Prestwick3_000052; Spectrum2_000125; Spectrum3_000325; Spectrum4_000262; Spectrum5_000936; Carbamazepine (Carbatrol); Lopac-C-4024; ChemDiv1_018966; CBChromo1_000350; Epitope ID:174842; Iminostilbene-N-carboxamide; Lopac0_000292; Oprea1_790775; SCHEMBL21639; BSPBio_000203; BSPBio_001929; KBioGR_000724; KBioSS_000516; MLS001055475; MLS001074172; MLS002548877; BIDD:GT0479; DivK1c_000388; DivK1c_003750; SPECTRUM1500159; SPBio_000170; SPBio_002124; BPBio1_000225; GTPL5339; ZINC4785; DTXSID4022731; SCHEMBL19838283; HMS501D10; HMS640O02; KBio1_000388; KBio2_000516; KBio2_003084; KBio2_005652; KBio3_001149; WLN: T C676 BNJ BVZ; AOB5783; Carbamazepine (JP17/USP/INN); CBZ; NSC 169864; SPD-417; Carbamazepine, analytical standard; NINDS_000388; HMS1568K05; HMS1920I17; HMS2090M07; HMS2091O19; HMS2095K05; HMS2233G16; HMS3039K09; HMS3259B21; HMS3260L06; HMS3372J13; HMS3657G03; HMS3712K05; HMS3747E03; Pharmakon1600-01500159; ACT02606; BCP21380; HY-B0246; KS-00000KI8; 5-Carbomoyl-5H-dibenzo(b,f)azepine; Tox21_110104; Tox21_202273; Tox21_300195; Tox21_500292; BBL005372; BDBM50003659; BG0497; CCG-38931; GP8250; NSC755920; s1693; STK177357; STL453548; 11-benzo[b][1]benzazepinecarboxamide; 5H-Dibenz[b,f]azepine-5-carboxamine; Carbamazepine 1.0 mg/ml in Methanol; AKOS003235644; AKOS025397243; IMED104589831; Tox21_110104_1; AC-9538; CS-2225; DB00564; KS-5146; LP00292; MCULE-9121567287; NC00679; NSC-755920; SDCCGSBI-0050280.P005; 5H-Dibenz[ b, f]azepine-5-carboxamide; Carbamazepin 100 microg/mL in Methanol; CDS1_002710; IDI1_000388; 5H-Dibenzo[b,f]azepine-5-carboxamide #; NCGC00015234-01; NCGC00015234-02; NCGC00015234-03; NCGC00015234-04; NCGC00015234-05; NCGC00015234-06; NCGC00015234-07; NCGC00015234-08; NCGC00015234-09; NCGC00015234-10; NCGC00015234-12; NCGC00015234-13; NCGC00015234-14; NCGC00015234-15; NCGC00015234-16; NCGC00015234-19; NCGC00023877-03; NCGC00023877-04; NCGC00023877-05; NCGC00023877-06; NCGC00023877-07; NCGC00023877-08; NCGC00253982-01; NCGC00259822-01; NCGC00260977-01; CC-25382; CC-25383; CPD001227191; H495; LS-60362; SAM002264603; SC-16243; ST075773; SY002823; (z)-5h-dibenzo[b,f]azepine-5-carboxamide; SBI-0050280.P004; 5H-dibenzo[b,f]azepine-5-carboximidic acid; AB0070254; AB1009530; DB-047659; ST2418853; Dibenzo[b,f]azepine-5-carboxylic acid amide; EU-0100292; FT-0602927; FT-0696814; H2605; SW220141-1; EN300-21678; BIM-0050280.0001; C 4024; C06868; Carbamazepine, meets USP testing specifications; D00252; 5H-Dibenz(b,f)azepine-5-carboxamide maleic acid; 5H-Dibenz(b,f)azepine-5-carboxamide oxalic acid; AB00051931-17; AB00051931-18; AB00051931_19; AB00051931_20; A820074; C-13993; Q410412; carbamazepine host structure with maleic acid removed; carbamazepine host structure with oxalic acid removed; SR-01000000229-2; SR-01000000229-4; SR-01000000229-7; 5H-Dibenz(b,f)azepine-5-carboxamide DL-tartaric acid; BRD-K71799949-001-06-7; F0348-2551; Z2199879032; carbamazepine host structure with DL-tartaric acid removed; Dibenzo[b,f]azepine-5-carboxylic acid amide(Carbamazepine); carbamazepine host structure with 4-hydroxybenzoic acid removed; Carbamazepine, British Pharmacopoeia (BP) Reference Standard; Carbamazepine, European Pharmacopoeia (EP) Reference Standard; Carbamazepine, United States Pharmacopeia (USP) Reference Standard; Carbamazepine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Carbamazepine, Pharmaceutical Secondary Standard; Certified Reference Material; Azapentacene; Sodium 5,12-dihydroazapentacene disulfonate; 5,12-Dihydroquinoxalino[2,3-b]phenazine sulfonate sodium salt; N6W; Carbamazepine; G-32883
Carbazole CARBAZOLE; 9H-Carbazole; 86-74-8; Dibenzopyrrole; Diphenylenimine; 9-Azafluorene; Diphenylenimide; Diphenyleneimine; Dibenzo[b,d]pyrrole; USAF EK-600; Dibenzo(b,d)pyrrole; NSC 3498; UNII-0P2197HHHN; SKF 20091; CCRIS 121; Carbazole, 96%; HSDB 2164; EINECS 201-696-0; AI3-00096; 0P2197HHHN; CHEBI:27543; UJOBWOGCFQCDNV-UHFFFAOYSA-N; MFCD00004960; DSSTox_CID_248; DSSTox_RID_75462; DSSTox_GSID_20248; CAS-86-74-8; SMR000112232; para-carbazole; 9H carbazole; 9-H-carbazole; 9CA; PubChem9944; Chlorophenesin carbamate; ACMC-209qbc; 9H-carbazole-d8 (9ci); bmse000666; EC 201-696-0; SCHEMBL7650; KSC185S6J; MLS001066363; MLS002415721; Carbazole, analytical standard; Carbazole, extra pure, 98%; WLN: T B656 HMJ; Carbazole, >=95% (GC); CHEMBL243580; SCHEMBL6026794; DTXSID4020248; NSC3498; HMS2267P20; NSC-3498; STR04484; Tox21_201703; Tox21_302847; ANW-38374; SBB040883; STK671343; AKOS000119129; ZINC100009863; ACN-051079; DB07301; LS-1856; LS41657; MCULE-7610805198; MP-2172; PS-4072; RTR-029467; TRA0048825; TRA0064433; KS-000002L8; NCGC00091233-01; NCGC00091233-02; NCGC00091233-03; NCGC00256533-01; NCGC00259252-01; BR-78310; K546; SC-46764; ST098573; DB-038198; DS-017121; FT-0085070; FT-0623455; Carbazole, VETRANAL(TM), analytical standard; C08060; A841825; Q424003; Q-200795; F0001-2148; Z1250100640; Carbazole solution, certified reference material, 2000 mug/mL in methylene chloride; Carprofen Related Compound A, United States Pharmacopeia (USP) Reference Standard; InChI=1/C12H9N/c1-3-7-11-9(5-1)10-6-2-4-8-12(10)13-11/h1-8,13; Carbazole(Carprofen Related Compound A), Pharmaceutical Secondary Standard; Certified Reference Material; AI3-00096
Carbimazole 2,3-Dihydro-3-methyl-2-thioxo-1H-imidazole-1-carboxylic acid ethyl ester; Carbimazole; 4-24-00-00064 (Beilstein Handbook Reference)
Carbocysteine S-(Carboxymethyl)-L-cysteine; carbocysteine; S-Carboxymethyl-L-cysteine; 638-23-3; Carbocisteine; carbocistein; S-(CARBOXYMETHYL)-L-CYSTEINE; Bronchokod; Mucolase; Mucotab; Siroxyl; Lisil; L-Carbocisteine; Mucodyne; (R)-S-(Carboxymethyl)cysteine; CarbocisteiCarbocisteinum; S-(Carboxymethyl)-(R)-cysteine; L-3-((Carboxymethyl)thio)alanine; H-Cys(carboxymethyl)-OH; Transbronchin; Lisomucil; l-carbocysteine; (L)-2-Amino-3-(carboxymethylthio)propionic acid; Fluifort; Mucofan; Rinatiol; UNII-740J2QX53R; S-Carboxymethylcysteine; Mucojet sirup; Mucolex sirup; Superthiol sirup; CHEMBL396416; CHEBI:16163; GBFLZEXEOZUWRN-VKHMYHEASA-N; 740J2QX53R; S-Carboxymethyl-L-cysteine, 98%; MFCD00002614; PSCMC; 3-(Carboxymethylthio)-L-alanine; Alanine, 3-((carboxymethyl)thio)-, L-; Chilvax; Mucosol; PectDrill; AHR 3053; Carboxymethylated Cysteine; LJ 206; C-1850; Carbocisteinum [INN-Latin]; Carbocisteina [INN-Spanish]; (2R)-2-amino-3-(carboxymethylthio)propanoic acid; (R)-2-Amino-3-((carboxymethyl)thio)propanoic acid; Q-200796; (2R)-2-amino-3-(carboxymethylsulfanyl)propanoic acid; (2R)-2-amino-3-[(carboxymethyl)sulfanyl]propanoic acid; Pulmoclase; Carbocit; Mucolex; Mucopront; Mucotron; Mukinyl; Pectox; AHR-3053; EINECS 211-327-5; L-(Carboxymethyl)cysteine; NSC 14156; SCMC; Carbocisteine [INN]; BRN 1725012; L.J. 206; (R)-2-amino-3-(carboxymethylthio)propanoic acid; s-carboxymethyl-cysteine; Poly(S-carboxymethylcysteine); NSC-14156; Carbocysteine [USAN:INN:BAN]; Poly(S-carboxymethyl-L-cysteine); L.J.206; Mucodyne (TN); DF 1794Y; Carbocistein [JAN]; (S)-Carboxymethylcysteine; L-Carbocisteine (JP17); SCHEMBL20854; KSC495A3H; (2R)-2-Amino-3-[(carboxymethyl)thio]propionic acid; CTK3J5033; (Carboxymethyl)cysteine-, (L)-; DTXSID30110060; R05CB03; 3-(Carboxymethylthio)alanine, L-; ZINC1529732; ANW-34746; BDBM50213735; LJ-206; s5216; SBB015059; AKOS015922826; 5-Amino-3-thiadihexanoic acid, (L)-; ACM2387599; DB04339; RTC-066540; 29433-95-2; AC-11146; ACM186537586; AK-81240; AS-57938; CC-25404; CC-34382; SC-19827; ST075001; AB1007076; AX8002883; ST2414447; TC-066540; FT-0082568; FT-0656306; FT-0658269; L-Cysteine, S-(carboxymethyl)-, homopolymer; KS-00001101; C03727; D00175; (2R)-2-amino-3-(carboxymethylthio)propionic acid; C-06527; Q423408; 2-Amino-3-(carboxymethylthio)propionic acid, (L)-; UNII-4252LRM78Q component GBFLZEXEOZUWRN-VKHMYHEASA-N; (2R)-2-azanyl-3-(2-hydroxy-2-oxoethylsulfanyl)propanoic acid; Carbocisteine, European Pharmacopoeia (EP) Reference Standard; (2R)-2-amino-3-[(carboxymethyl)sulfanyl]propanoic acidS-(carboxymethyl)-L-cysteine; L-Cysteine, S-(carboxymethyl)-; L.J. 206
Carbomycin A Carbomycin; Carbomycin A; CARBOMYCIN; Magnamycin; Magnamycin A; UNII-AIK0XUF3AV; Deltamycin A4; AIK0XUF3AV; 4564-87-8; Carbomycin acetate; Carbomycin [INN]; Magnamycin (VAN); NSC 51001; Carbomycine [INN-French]; Carbomycinum [INN-Latin]; Carbomicina [INN-Spanish]; CarbomiciCarbomycine; Carbomycinum; M-4209; GS MAI 5201 52 3; GS-MAI 5201-52-3; AI3-50160; Leucomycin V, 9-deoxy-12,13-epoxy-12,13-dihydro-9-oxo-, 3-acetate; Leucomycin V, 9-deoxy-12,13-epoxy-12,13-dihydro-9-oxo-, 3-acetate 4B-(3-methylbutanoate), (12S,13S)-; Carbomycin A (8CI); CHEMBL1231649; FQVHOULQCKDUCY-OGHXVOSASA-N; An antibiotic obtained from cultures of Streptomyces halstedii, or the same substance produced by any other means; DB11383; UNII-3952621T3O component FQVHOULQCKDUCY-OGHXVOSASA-N; (2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6S)-6-{[(1S,3R,7R,8S,9S,10R,12R,14E,16S)-7-(acetyloxy)-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyltetrahydro-2H-pyran-3-yl]oxy}-4-hydroxy-2,4-dimethyltetrahydro-2H-pyran-3-yl 3-methylbutanoate (non-preferred name); Carbomycin A; CARBOMYCIN; Deltamycin A4; Magnamycin; Magnamycin A; Carbomycin acetate; Carbomycin [INN]; Magnamycin (VAN); Carbomycine [INN-French]; Carbomycinum [INN-Latin]; Carbomicina [INN-Spanish]; NSC 51001; GS MAI 5201 52 3; GS-MAI 5201-52-3; NCGC00181116-01; AI3-50160; M-4209; DSSTox_CID_26855; DSSTox_RID_81963; DSSTox_GSID_46855; SCHEMBL140113; CHEMBL2355445; DTXSID5046855; Leucomycin V, 9-deoxy-12,13-epoxy-12,13-dihydro-9-oxo-, 3-acetate; C42H67NO16; An antibiotic obtained from cultures of Streptomyces halstedii, or the same substance produced by any other means; Leucomycin V, 9-deoxy-12,13-epoxy-12,13-dihydro-9-oxo-, 3-acetate 4B-(3-methylbutanoate), (12S,13S)-; Tox21_112727; LS-87893; CAS-4564-87-8; Carbomycin A; NSC51001; CARBOMYCIN; Magnamycin; Magnamycin A; Deltamycin A4; Carbomycin acetate; Leucomycin V,13-epoxy-9-oxo-, 3-acetate 4(sup b)-(3-methylbutanoate; GS MAI 5201 52 3; GS-MAI 5201-52-3; 9-Deoxy-12,13-epoxy-9-oxoleucomycin V 3-acetate 4(sup b)-(3-methylbutanoate); 10-Hexadecenoic acid,5-dihydroxy-4,6-dimethylpyran-2-yl)oxy]-pyran-2-yl]oxy]-12,13-epoxy-6-(formylmethyl)-3,15-dihydroxy-4-methoxy-8-methyl-9-oxo-,.omega.-lactone, acetate, isovalerate; Leucomycin V,13-epoxy-12,13-dihydro-9-oxo-, 3-acetate 4B-(3-methylbutanoate), (12R,13S)-; Leucomycin V,13-epoxy-12,13-dihydro-9-oxo-, 3-acetate 4B-(3-methylbutanoate), (12S,13S)-; WLN: T3-17- BO GOV PV QUTJ EOV1 JOVY2&1 KO1 M1VH O1 NO- BT6OTJ CQ DN2&2 F1 EO- BT6OTJ DQ D1 EQ F1; M-4209; CHEMBL1979878; NSC55924; NSC-51001; NSC-55924; 10-Hexadecenoic acid,5-dihydroxy-4,6-dimethylpyran-2-yl)oxy]pyran-2-yl]oxy]-12,13-epoxy-6-(formylmethyl)-3,15-dihydroxy-4-methoxy-8-methyl-9-oxo-, .omega.-lactone, acetate, isovalerate; CARBOMYCIN; Magnamycin A; SCHEMBL140114; [6-[6-[[(14Z)-7-acetoxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyl-tetrahydropyran-3-yl]oxy-4-hydroxy-2,4-dimethyl-tetrahydropyran-3-yl] 3-methylbutanoate; 3-Methyl-butyric acid 6-{[(Z)-7-acetoxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxo-ethyl)-4,17-dioxa-bicyclo[14.1.0]heptadec-14-en-9-yloxy]-dimethylamino-hydroxy-methyl-tetrahydro-pyran-3-yloxy}-4-hydroxy-2,4-dimethyl-tetrahydro-pyran-3-yl ester; CARBOMYCIN; CARBOMYCIN; CARBOMYCIN; CHEMBL3989435; M-4209
Carbon monoxide
Carmustine N,N'-Bis(2-chloroethyl)-N-nitrosourea; Carmustine; AI3-52216